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Progression of Prostate cancer (CaP), depends on a complex series of interactions
between the tumor and extracellular matrix (ECM) leading to tumor growth and
metastasis. Hyaluronan (HA), an ECM component, is elevated in CaP and its
accumulation in the tumor microenvironment is dependent on its synthetic enzyme,
hyaluronan synthase (HAS), and turnover enzyme, hyaluronidase (Hyal). Although Hyal1
expression can independently prognosticate CaP, and HAS expression shows increase in
aggressive prostate cancer cells, the functional relevance of this correlation is unexplored.
In these studies we aim to dissect the roles of HAS and Hyal1 in prostate cancer.
Stably overexpressed hyaluronan synthases (HAS2, HAS3), and Hyal1,
individually or concurrently (Hyal1+HAS2 and Hyal1+HAS3) in a non-metastatic
prostate tumor cell line, were characterized by subcutaneous and orthotopic injections in
NOD/SCID mice and assayed for cell proliferation, adhesion, and motility in vitro.
Subcutaneous tumors were larger for Hyal1+HAS2 cells and smaller in Hyal1+HAS3
cells, potentially due to effective HA dissipation in the former. With orthoptopic
injections, Hyal1+HAS transfectants were maximally tumorigenic and metastatic.
Contrastingly, HAS expression suppressed tumor growth and metastasis, while Hyal1
promoted metastasis without significant tumor growth. These in vitro characterizations

suggested tumor suppression by HAS was due to reduced growth with slower cell cycle
kinetics, and the enhanced metastasis of Hyal1+HAS ascribed to increased adhesion and
motility of the transfectants.
We tested ERK activation and cell cycle proteins as potential targets and found
that Hyal1 showed modestly decreased sustained ERK activation compared to HAS3.
Furthermore, in asynchronous and cycling cells, cyclin-dependent kinase inhibitors
(CKIs) p21cip and p27kip were elevated with HAS expression while p21cip expression was
reduced in Hyal1 and Hyal1+HAS3 cells.
We demonstrate the dual requirement of both HAS and Hyal for maximum
prostate tumorgenesis and metastasis mediated via altered adhesion, motility, and cell
cycle progression. Our studies are the first comprehensive examination of the role of
HAS and Hyal1 in prostate tumor progression thereby establishing a new paradigm for
HA metabolism in CaP.
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CHAPTER 1

INTRODUCTION

2
1.1

PROSTATE CANCER
Prostate cancer (CaP) is the second leading cause of cancer death in men in the

United States. According to American Cancer Society 2008 statistics approximately one
in six men are diagnosed with CaP. However, molecular mechanisms linked with the
development and progressions of the disease are complex. Greater mechanistic
understanding of growth, angiogenesis and invasion processes would aid in early
detection and identification of prognostic factors, ultimately providing better
management of the disease in individual cases.
The prostate gland is a part of the male reproductive system. It is a small exocrine
gland located at the base of the bladder surrounding the urethra. The main function of the
gland is to provide secretory proteins for the semen1. Within the gland are secretory
luminal epithelial cells, basal cells and underlying basement membrane. The secretory
luminal epithelial cells are androgen dependent and function in the secretion of prostatic
proteins. The basal cells are present between the luminal cells and basement membrane.
Androgen independent neuroendocrine cells are a third cell type, interspersed within the
basal layer, which provide paracrine signals to the luminal cells1,2.
A relatively unique feature of CaP is the early preservation of epithelial cell
dependence on androgen hormones1. Androgen ablation by chemical or surgical
castration leads to regression of the tumor in the earlier stages3. However, chemical and
surgical castration prolongs the survival by only 10%. Unfortunately this effect is
transient and a population of androgen independent cells arises, leading to uncontrolled
growth in the absence of androgens resulting in the relapse of the tumor2. It is believed
that the proliferation of the prostate cancer cells is relatively low compared to other
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cancers2. This implies that CaP can go relatively undetected till aggressive and invasive
form the cancer develops. Another unusual characteristic of prostate cancer is that it is a
heterogeneous disease, exhibiting glandular tissue disorganization and multiple tumor
foci with different genetic and/or epigenetic alterations located in the same gland1. The
therapeutic challenge is to find a proliferation independent strategy that targets aspects of
tumor progression such as metastasis and angiogenesis in these diverse populations of
cells. Alternative therapies based on in-depth understanding of prostate cancer are of
critical importance. The current therapies used for treatment of CaP include
chemotherapy and radiation therapy. These offer palliative benefits, but do not change the
life expectancy4. Given that early diagnosis would reduce the mortality associated with
CaP and enhance life expectancy, discovery of biomarkers for diagnosis and prognosis is
an important research avenue.
The prognostic potential of prostate cancer is mainly dictated by the presence or
absence of metastases1. There is an inverse relationship between tumor differentiation
and metastasis. Well differentiated tumors rarely metastasize, whereas poorly
differentiated tumors are always metastatic. The prognostic indicators that have been
used for organ confined prostate cancer are Gleason score (based on degree of tissue
disorganization due to heterogeneity)5, tumor volume and Ki-67 index6-8. Progression
associated prognostic features include Gleason score, stage, capsular invasion and
Prostate Specific Antigen (PSA). Some biological markers commonly used to detect
progression are E-cadherin9,10, microvessel density and aneuploidy4. Since none of these
is effective in all cases, there is a need for markers which will determine aggressive
disease in the early stages of development.
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1.2

HYALURONAN
Extracellular matrix (ECM) is defined as a complex mixture of proteins,

proteoglycans, and glycosaminoglycans. It is well established that ECM important role in
tumor progression, especially in cancers such as CaP that are of epithelial origin. The
ECM can modulate cell behaviors to maintain tissue architecture and cell adhesion,
sustain cell proliferation, or signal cell death. Tumor progression occurs with constant
interaction between the cancerous cells and the ECM. In fact, remodeling and changes in
the ECM are important pre-requisites for tumor progression11,12.
Hyaluronan (HA) is a critical element of the ECM, shown to be involved in
CaP13-16. HA was first described by Meyer and Palmer17 as a polysaccharide found in the
vitreous humor of the bovine eye. The study described in this article mainly focused on
the physical and chemical properties of HA and defined HA as a high molecular weight
polymer composed of monomers of glucuronic acid and N-acetylglucosamine linked by
alternating β-1,3 and β-1,4 linkages17. HA is unique among the various complex
carbohydrates found in mammals, in that it is not synthesized within the golgi apparatus
and is not formed on a protein core or complex18,19. In some tissues such as the vitreous,
synovial and dermis, HA is a mechanical and structural component16. However, it is now
known to have an active role in modulating cell behavior.
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1.3

HYALURONAN AND CANCER
Localization of HA in tumor is dependent on the origin and type of the tumor.

Normal tissue from simple epithelia such as those of bladder, breast, prostate, ovary and
colon show very weak signal for HA or sometimes no signal20-24. Development and
progression of tumors in these tissues is associated with HA accumulation around tumor
cells and in tumor associated stroma. Tumor grade and differentiation state show positive
correlation with HA staining intensity25. In ovarian and breast cancers, stromal HA signal
is an independent prognostic indicator of patient survival. In colorectal and gastric cancer
tumor cell associated HA correlates with local invasive growth and metastasis to lymph
nodes and salivary glands20,26-28. In bladder cancer urinary concentration of HA is
elevated by three to seven fold irrespective of tumor grade and is now being employed as
a diagnostic and prognostic marker for bladder cancer.
One of the earliest studies in prostate cancerous tissues indicated that HA
increased with dedifferentiation of the tumor29. HA levels were elevated seven to eight
fold in low grade and high grade prostate cancer and metastatic prostate cancer tissues,
compared to normal prostate and benign prostatic hyperplasia. Aaltoma et al studied
localization of HA in tumor samples in relationship to other prognostic factors such as
Gleason score, PSA recurrence, seminal vesicle invasion etc. In this case, PSA recurrence
and other factors related to unfavorable prognosis were predicted by strong stromal HA30.
Similar studies were conducted by several other researchers with a longer follow-up
period. Interestingly, these studies found that combined HA-HYAL1 (HYAL1
hyaluronidase) staining predicted progression along with PSA, Gleason score, disease
stage and seminal vesicle invasion15. Thus, a high level of HA on tumor cells and
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intratumoral stromal cells may indicate poor patient outcome or reduced disease-free
survival period, specifically true for bladder, prostate, breast, gastric, and colorectal
cancers.

1.4

HYALURONAN METABOLISM
HA is abundantly turned over, with a half-life of 1-3 days in cartilage and less

than one day in the skin epidermis31,32. Proteins that synthesize HA are called hyaluronan
synthases (HAS), proteins that break down or process HA are termed hyaluronidases
(Hyal), and there are specific receptors which mediate the various biological functions of
HA. The HA receptors also regulate HA metabolism by internalization and endocytosis.

1.4.1

Hyaluronan Synthases
HAS enzymes are plasma membrane embedded proteins that polymerize HA by

alternating β1-4 and β1-3 linked addition of glucuronic acid and N-acetylglucosamine
from UDP-esterified precursors. There are three distinct isozymes for the HAS, denoted
as HAS1, HAS2, and HAS3 in mammals. HAS enzymes are intriguing in that a single
protein forms both glycosidic bonds using two sugar substrates to synthesize HA33. HA
synthesis occurs at the reducing end of the growing chain by a two-site mechanism34.
During embryogenesis, the three HAS genes are expressed tissue specifically with
partially distinct timing35. Only HAS2 is an essential gene, targeted disruption of which
stops cardiac development36. The three human HAS genes occur on three different
chromosomes: 19, 8 and 16 for HAS1, HAS2 and HAS3, respectively. The three
isozymes are 55-71% identical at the amino acid level and ≈30% identical to the

7
prokaryotic proteins19,35,37. The topology of the human HAS enzymes has not been
experimentally determined, but secondary structure predictions have suggested seven
transmembrane regions with a central, cytoplasmic loop housing the putative catalytic
region of the enzyme33,38. Polymerization of HA occurs at the inner cytoplasmic part of
the membrane and the polymer is extruded out into the extracellular space during
elongation33,38.
Although all the three synthases catalyze the same reaction, one study suggested
that each of the isozymes produces a different size product with slightly different enzyme
kinetics39. Though range of molecular sizes is overlapping, the average size of HA
synthesized by HAS1 and HAS2 was reported to be ≈2 million Daltons, whereas that of
HAS3 was ≈200kDa.
1.4.1.1 Regulation of Hyaluronan Synthesis
To date, regulation of HAS has been reported to occur only at the transcriptional
level in response to various growth factors and cytokines. Upregulation of HAS2 mRNA
is observed by transforming growth factor beta (TGF-β)40, bone morphogenetic protein
superfamily members41, interleukin-1 beta (IL-1β)42, epidermal growth factor (EGF)40,
platelet derived growth factor (PDGF)43,44, insulin-like growth factor-1 (IGF-1) and basic
fibroblast growth factor (bFGF)45. PDGF-bb stimulated upregulation of HAS2 mRNA in
smooth muscle cells derived from normal prostate and specimens of Benign Prostatic
Hyperplasia (BPH). In renal cells, the major regulators of HAS2 promoters were Sp1 and
Sp2 transcriptional factors46. In mammalian cell cultures, the expression of HAS mRNA
was also regulated by cell density, where the expression was higher in sub-confluent
cultures compared to confluent cultures47.
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HA synthesis is additionally regulated by restricting the availability of HA
precursors. The enzyme UDP-glucose dehydrogenase catalyzes synthesis of the UDPglucuronate precursor, and is regulated by androgens in prostate epithelium48-50.
Androgen stimulated HA production in the Noble and Dunning rat models of prostate
carcinoma51. Li, et al, have shown a significant increase in HA staining intensity in
androgen induced dysplastic and neoplastic rat prostate stroma51. Further evidence of the
role of androgen in regulating HA accumulation derived from studies in which androgen
deprivation by castration reduced HA levels in the dorsal rat prostate52,53.
Clinicopathological studies have shown that elevated HAS1 transcripts and
intronic gene splicing correlate with poor prognosis in human colon, ovarian cancers and
multiple myelomas54-56. HAS1 transcript and protein were found elevated in neoplastic
bladder tissues compared to normal tissues. This suggests that HAS1 is the likely
candidate contributing to elevated HA levels in high grade bladder cancer57. Though no
study has been yet reported on HAS expression levels in patient prostate tumor
specimens, aggressive and metastatic androgen independent prostate cancer cells
expressed 3-fold and 30-fold higher HAS2 and HAS3 transcripts, respectively58 and
produce substantially more HA. Genetic variations in chromosome 8q24 have been
associated with increased risk factor for prostate and colorectal cancer59,60. Since HAS2 is
located in 8q24 and genetically overrepresented in prostate cancer61, variation in this
locus might also affect HAS2 expression in cancers and cancer cell lines62.
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1.4.2

Hyaluronidases
Six hyaluronidase-like gene sequences have been identified in humans. HYAL1,

HYAL2 and HYAL3, are located on chromosome 3p21.3. The other three, HYAL4,
SPAM1, and a pseudogene (“PHYAL”), are located on chromosome 7p31.3. The five
proteins encoded by these genes are similar in size and share up to 40% amino acid
identity63-66. PH20, Hyal1, and Hyal2 are relatively well characterized. PH20 (encoded by
SPAM1) was originally thought to be found only in sperm. Hyal1 and Hyal2 proteins are
predominantly found in the somatic tissue67-70. Hyal3 knockout mice suggest a potential
role for this isozyme in health of joint/lung tissue71. Both Hyal3 and Hyal4 appear to lack
hyaluronidase activity despite conservation of key catalytic residues, but a systematic
characterization has not been done.
PH20 is active at neutral pH and facilitates sperm penetration by degrading the
HA surrounding the cumulus mass of the ovum. It is crucial for fertilization72. PH20 has
been detected in the epididymis, seminal vesicles, prostate, female genital tract, breast,
placental and fetal tissues (refs). Hyal1 has high specific activity as a hyaluronidase, but
only at acidic pH (<4.5). It is a lysosomal protein, but is also found in the serum and
urine, and is elevated in patients with prostate and bladder cancer14,73,74. Hyal2 is
anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety, and
has activity at pH <4.5, as well as >6.075,76. Hyal1 and PH20 cleave HMW HA into
tetraaccharides77, whereas Hyal2 reportedly cleaves HA to fragments of no less than
20kDa76. Functional analysis of Hyal1 in our laboratory has experimentally demonstrated
the essential catalytic residues of the enzyme and determined that glycosylation is not
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only needed for proper subcellular distribution of Hyal1, but also for its intrinsic catalytic
activity78.
1.4.2.1 Hyaluronidases in Tumors
Loss of chromosome 3p21.3 occurs commonly in some epithelial tumors such as
lung and breast cancers79,80. For this reason, hyaluronidases were initially termed tumor
suppressors. Alternative mRNA splicing has been reported for Hyal1 and Hyal3. The
variants, which were obtained from normal and cancerous bladder tissues and from
prostate cancer cell lines, encode truncated proteins that lack enzyme activity. The
significance of such variation is not understood81.
The concept that both HA and hyaluronidases are jointly required for tumor
progression has been introduced by several labs, including ours. Hyal1 is the most well
documented hyaluronidase in cancer but others have not been widely examined.
Specifically, Hyal1 is elevated in bladder, prostate, head and neck, and squamous cell
carcinomas14,82,83. Hyal1 levels were significantly elevated in high grade versus low grade
prostate cancer tissues. Also in comparison, normal prostate and benign prostatic
hyperplasia had much lower levels of Hyal1 compared to metastatic prostate cancer
lesions14,73. Similar results were found in bladder cancer specimens74,84-87. Joint
evaluation of HA and hyaluronidase is marketed as a diagnostic and prognostic test for
bladder cancer86.
Hyal2 is important for retro-viral entry and oncogenesis in sheep76,88,89. Although
normal adult brain is deficient in Hyal2 transcripts, but several glial cell tumors and
menigiomas show increased transcript levels75,90. No distinct correlation was observed
with tumor grade or stage. Over-expression of Hyal2 in a mouse astrocytoma cell line
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accelerates intracerebral growth91,92. Highly invasive breast cancer cell lines were shown
to express Hyal293. Hyaluronidase similar to the one in sperm head (PH20) was also
expressed in metastatic melanoma, colon carcinoma and glioblastoma cell lines, but
absent in normal tissues of the same origin94. PH20 transcript levels were significantly
elevated in laryngeal cancer specimens compared to their normal counterparts, with
metastatic lesions showing a higher expression in comparison to the primary tumor95.
PH20 was elevated in invasive and metastatic breast cancer96.

1.5

HYALURONAN RECEPTORS
HA elicits specific effects on cell behavior by activating intracellular signaling

pathways via binding to proteins generally known as hyaladherins97 Receptors such as
Cluster of Differentiation 44 (CD44) and Receptor for Hyaluronan Mediated Motility
(RHAMM) are well characterized signaling receptors. More recently, receptors such as
LYVE1 (Lymphatic Vessel Endothelial Receptor1), HARE (Hyaluronan Receptor for
Endocytosis) and toll-like receptors TLR1 and TLR4, have been identified. Although
implicated in cancer processes, particularly in lymphangiogenesis (development of new
tumor-associated lymphatic vessels), in contrast to CD44 and RHAMM which are
expressed on the tumor cells, these latter classes of receptors appear primarily to be
localized in metastatic target tissues and may be counter receptors that mediate tissuespecific metastasis98-101. Thus, we have confined the scope of our discussion to CD44 and
RHAMM.
RHAMM is a HA binding protein with multiple alternatively spliced isoforms
that reportedly localizes both intracellularly and at the cell surface, though the coding
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sequence does not contain a signal peptide or a transmembrane domain102. Inside the cell,
RHAMM occurs in the cytoplasm, mitochondria, and nucleus103-106. RHAMM is
associated with the cytoskeleton, microtubules, centrosomes and mitotic spindle103,107,
and apparently influences mitosis by inducing the expression of cell cycle proteins Cdc25
and Cyclin B1108. Sohr et al109 have shown that RHAMM expression is regulated during
the various phases of the cell cycle. Resting cells contain very little, but it’s mRNA and
protein levels rise during DNA synthesis (S-phase) and peak during the mitotic (G2/M)
phase. The tumor suppressor p53 can down-regulate cell cycle dependent expression of
RHAMM109. Since Brecht et al, showed increased HA synthesis is required during
mitosis for cell detachment110, RHAMM-HA cell cycle control may be significant in
cancer progression.
RHAMM, is not highly expressed in normal tissues111-113 and is not essential for
mouse embryonic development and adult mouse homeostasis114,115, but its absence slows
wound repair and it is overexpressed in several advanced cancers104,116-121.
Hyperexpression of RHAMM in breast cancer lesions predicts poor clinical outcome and
increased risk of sporadic lymph node metastasis122,123. Additionally, homozygous
variation in RHAMM was significantly correlated with early onset breast cancer124.
HA ligation to the cell surface isoform of RHAMM activates multiple signaling
pathways to affect cell motility and breast cancer progression113. RHAMM
overexpression caused and maintained Ras-dependent cell transformation125. In the
absence of CD44 expression in some advanced cancers, RHAMM is postulated to
promote HA-mediated cell signaling and oncogenic progression.
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CD44 is a prominent cell surface HA receptor, a type 1 transmembrane
glycoprotein that contributes to regulation of growth, survival, differentiation and
motility. CD44 isoforms are broadly expressed and range in size from ≈80-200kDa. All
isoforms are encoded by a single gene126 of 20 exons, from which alternatively spliced
products are generated. The standard isoform of CD44 consists of an N-terminal signal
sequence (exon 1), a HA binding domain with homology to the link protein family of
aggrecan and HA binding proteins (exons 2 and 3), a “stem” region of 248 amino acids
(Exons 4, 5, 16, 17), a 21 amino acid transmembrane domain (exon 18), and a 72 amino
acid cytoplasmic domain (exon 19). The splice variants are generated as a result of
insertion of various permutations and combinations of exons 6-15 (v1-v10) into the stem
region. The variants are most commonly expressed in epithelial cells and are upregulated
under pathological conditions such as cancer126-128.
Regulation of CD44 occurs at multiple levels in addition to splicing: promoter
methylation129-131,

transcription132,

post-translational

modifications

such

as

glycosylation133,134, glycosaminoglycan attachment133,134, and phosphorylation135,136,
ligand binding132, and proteolytic processing of the extracellular domain137. Examination
of CD44 expression in CaP clinical specimens has produced controversial results.
Overexpression of CD44 in CaP cell lines suppressed metastatic behavior without
suppression of in vivo tumorigenesis138. On the other hand, studies have implicated CD44
in CaP cell proliferation, adhesion and motility in vitro as well as in metastatic
dissemination in vivo139-143. Such discrepancies may arise from variable detection
methods or may be indicative of the heterogeneity that is a hallmark of CaP. Patrawala, et
al, found that highly purified CD44+ CaP cells from xenograft human tumors are 100
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times more tumorigenic and metastatic than the CD44- CaP cells, reflecting a correlation
between CD44 expression and an aggressive progenitor cell type144, possibly CaP stem
cells145.
CD44 signaling functions can be classified into three categories. Binding of CD44
to HA is reported to promote HA internalization, facilitating HA degradation and
constituent sugar salvage146. Recent evidence implicates CD44 in activation of
hyaluronidases through its interaction with Na+/H+ exchange pumps in coated pit
microdomains147,148. Hyal1 and Hyal2 are thought to associate inertly with CD44-bound
HA until activated by the consequent local acidification148. CD44 is reported to locally
concentrate matrix metalloproteases (MMPs) and growth factor receptors. MMP’s are
important mediators of tumor cell invasion149. Receptor tyrosine kinases such as SF/HGF
(c-Met), ERBB1 (EGFR), ERBB2, ERBB3 and ERBB4 growth factor receptors149,150 are
activated by local clustering151,152. In this way, CD44-HA interaction influences cell
signaling in tumor cells to promote tumor growth and invasion. Cytoskeletal adaptor
proteins Src, Rho GTPase, Rho-GDP-dissociation inhibitor (GDI), ankyrin, Ezrin,
Radixin, Moesin (ERM) and merlin, to name a few, associate with CD44153-156.
CD44 may additionally interact with integrins, the main cell surface receptors for
cell-ECM adhesion, but no direct interaction between CD44 and integrins has been
shown. Stimulation of CD44 by cross-linking with CD44 antibodies or treatment with
6.9kDa HA induced αLβ2 integrin expression in colon cancer cells and promoted integrin
activation157. In gastric cancer cells, CD44 interacted with osteopontin (OPN) to activate
integrins158 and amplify the matrix-derived survival signal. CD44 engagement with OPN
caused lipid raft domains to become enriched in CD44-Src-integrin β1, supporting a role
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for CD44-integrin crosstalk in response to the ECM, but the underlying mechanisms are
not known159.

1.6

HYALURONAN

METABOLISM

IN

CANCER

PROGRESSION

–

MOLECULAR MECHANISMS
Surface retention of HA is a critical determinant for tumor progression. HA is
anionic, hydrophilic, and viscous in concentrated solutions. HA bound to tumor cell
CD44 organizes loosely into a HA-rich pericellular matrix. Much of our understanding of
the role of this tumor cell HA matrix in disease progression has been deduced through
experimental manipulation of HAS and hyaluronidases in cell culture and animal models,
or competitive displacement of endogenous HA-receptor interactions.

1.6.1 Tumor Growth and Metastasis
Overexpression of HAS2 in fibrosarcoma cells increased HA production,
anchorage independent growth in vitro and tumor size in mouse xenografts in vivo160. The
increase in tumor size was mainly due to increase in the proliferation index of the tumors
and not due to accumulation of tumor stroma or angiogenesis. Another study showed that
mouse mammary carcinoma cells with low surface HA retention were poorly metastatic,
whereas ectopic expression of HAS1 in these cell lines caused them to form increased
numbers of metastatic lung nodules161. HA overproduction in non-metastatic cells
diminishes contact inhibition, promotes cell growth and migration162. Transgenic mice
overexpressing HAS2 specifically in mammary gland showed increased tumor incidence,
forming aggressive, poorly differentiated, and vascularized tumors163. Complementary to
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these studies, antisense inhibition of HAS2 and HAS3 in metastatic prostate carcinoma
cells reduced subcutaneous and orthotopic tumor growth in NOD/SCID mice164.
Competitive disruption of CD44-HA ligation was achieved by expression of the CD44
ectodomain165,166, reducing mammary and melanoma metastasis by apoptosis or cell
cycle arrest, respectively167. CD44 antibodies168 or HA oligomers169,170 that prevent
CD44-HA binding also reduce tumor growth and invasion. Inhibition of growth in the
latter case was mainly due to suppression of the PI3 kinase cell survival pathway169.
Interestingly, activation of ERBB2 receptor, which is constitutively high in many
cancers171,172, is mediated by endogenous CD44-HA interaction, and manipulation of
cells to produce high levels of HA resulted in increased phosphorylation of ERBB2.
Interfering with endogenous CD44-HA interaction by employing HA oligomers, soluble
CD44, and siRNA knock-down of CD44 resulted in reduced ERBB2 activation.
Additionally disruption of such an interaction also causes disassembly of raft associated
signaling complexes, which contain phosphorylated ERBB2, CD44, Ezrin, PI3kinase and
cdc37173.
Though endogenous HA can promote tumorigenesis, some studies have reported
that large quantities of high molecular weight HA polymers may antagonize cell
proliferation, while HA of 10-100kDa stimulated endothelial cell growth and
angiogenesis174. Moreover, even though elevated HA promoted tumor growth, extremely
high levels were tumor suppressive175. Expressing HAS in glioma cells lacking
hyaluronidase reduced tumor growth91. Importantly, prognosis of CaP is predicted by
concurrent HA and Hyal1 staining14,73,176. Thus, use of HA as a growth stimulus is
somehow dependent on its processing and turnover.
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Hyal1 has been characterized in prostate tumor cell lines selected to express
varying levels and found to be dose dependent in its outcomes. In particular, exceedingly
high expression of Hyal1 beyond levels found in tumors, inhibited tumor proliferation by
causing apoptosis176. Hyal1 transfectants with hyaluronidase activities in the range found
in clinical prostate cancer samples, on the other hand, yielded larger tumors. Thus,
despite previous studies by other groups in which overexpression of hyaluronidase
suppressed tumor growth, it is most accurately considered a tumor promoter, at least in
prostate cancer176-180. Inhibiting Hyal1 expression in bladder and prostate cancer cells
reduced tumor cell proliferation specifically by cell cycle arrest at G2/M phase181.
Moreover, Hyal1 expression in oral cancer cells caused an increase in the percentage of
cells in S-phase, suggesting Hyal1 promotes cell cycle progression and accelerated Sphase entry, through an unknown mechanism68.
Expression of Hyal1 in a human non-metastatic prostate cancer cell line induced
spontaneous metastasis to lymph nodes in mice, though primary tumor growth was
unaffected182. Hyal1 overexpression in highly metastatic PC3M prostate tumor cells
increased their metastatic frequency183. Our lab has since determined that, in fact,
coexpression of HAS and Hyal1 is maximally tumorigenic and metastatic, whereas
expression of the HAS enzymes individually is poorly tumorigenic and metastatic184,185.
Adhesion and motility of tumor cells are component processes of tumor invasion
and metastasis. In wound healing and inflammation, adhesion to HA arrests circulating
leukocytes in tissues spaces and endothelial cells via its surface receptor CD44186,187. This
may also be a mechanism exploited by circulating tumor cells that metastasize to remote
sites188. The pericellular HA matrix can mediate both adhesion and de-adhesion, which
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would be required at the metastatic site. During cell division, increased HA synthesis in
G2/M phase causes rounding and mitotic cell detachment189,190. Another study
demonstrated the significance plasma membrane residence of HAS and HA in formation
of cell protrusions191. Hyaluronidases are likely to be involved in modulating the pro and
anti-adhesive functions of HA.
In cardiac morphogenesis, HA receptor engagement and ras activation were
shown to promote motility of endothelial cells and induce epithelial mesenchymal
transition (EMT)36,192, which is also a hallmark of aggressive tumor cells. Candidate
signaling pathways include those mediated through CD44 and RHAMM. Rho GTPases
such as Rho and Rac1 participate in the interaction of CD44 with cytoskeleton proteins
such as ankyrin, ezrin and merlin. This promotes or suppresses Rac1 activation, which
signals cell motility by inducing focal adhesion turnover, membrane ruffling, cell
spreading, and formation of cellular protrusions153,193 via FAK (focal adhesion
kinase)125,194, Src195, and Erk196.

1.6.2

Tumor Angiogenesis
Angiogenesis

is

critical

for

tumor growth,

invasion,

and

metastasis.

Immunohistochemical studies have shown that the microvessel density is enhanced in
prostate cancer tissue compared to benign prostatic hyperplasia (BPH) and normal
prostate tissue197,198. Moreover prostate cancer that metastasized and showed clinical
symptoms have greater capillary density ratios compared to localized or undetected
prostate cancer199,200. Various studies have suggested that microvessel density is an

19
independent predictor of prostate cancer progression and a prognostic indicator of
clinically localized disease201-203.
Studies have implicated HA in normal wound healing, where it correlates with
embryonic scarless healing. The role of HA is highly complex and appears to be is
largely dependent on HA concentration and size204. HA oligosaccharides (6-20 sugars)
enhanced proliferation and migration of bovine aortic endothelial cells (BAEC) in
vitro205,206 and promoted collagen synthesis207. In contrast, native high molecular weight
HA was anti-angiogenic, inhibiting endothelial cell proliferation, migration and capillary
formation in a three dimensional collagen gel model174,208,209. In inflammatory and wound
healing responses, HA oligosaccharides indirectly activated endothelial cells by
stimulating cytokine release (TNF-α, IGF-1, IL-8 and IL1-β) from macrophages210.
In pathological conditions such as cancer, increased staining of HA of
undetermined size is observed both in intra and peri-tumoral regions. Its origin is
uncertain and may be tumor cells, macrophages, activated stromal cells, or other cell
type. Nevertheless several groups have examined a correlation between HA and tumor
vascularization211. The biological processes that generate HA oligomers may be by
hyaluronidases, mechanical shearing, and breakdown by reactive oxygen species (ROS)
during inflammation, or release of degraded HA from necrotic cells. Cancers such as
breast212, bladder74, prostate14, and endometrial213 showed increased expression of
hyaluronidase, which may generate HA oligosaccharides, correlating with increased
tumor vascularization. Consistent with this notion, antisense mediated knockdown of HA
synthesizing enzymes HAS2 and HAS3 in aggressive prostate carcinoma cell lines
reduced tumor vascularization164. Coinjection of exogenous HA with these cell lines
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restored growth and vascularization in vivo. One possible explanation is that
hyaluronidase uses this added substrate to make HA oligosaccharides, which affect
angiogenesis.
To summarize the role of HA in prostate cancer progression is complex involving
an interplay between the hyaluronan synthases, hyaluronidases and the HA receptors,
jointly modulating tumor growth, metastasis and angiogenesis (Figure 1.1).

1.7

MOLECULAR PATHWAYS REGULATING CELL PROLIFERATION
The basic cell cycle is divided into four phases: DNA synthesis (S phase), in

which a single copy of error free genetic material is made; mitosis (M phase), in which
genetic material, cytoplasm, and other cellular components are divided into two identical
cells; and two gap phases (G1 and G2). In G1, the cell completes proofreading and
damage correction from the previous round of cell division in preparation for S-phase. In
G2, the cell reconciles DNA crossovers and prepares for successful completion of
mitosis214,215. When cells exit the cycle and remain in a non-dividing phase, it is known
as G0. The various phases are interspersed with certain regulatory checkpoints that
prevent them from entering into a new phase until successful completion of previous
phase. This ensures the proper progression through the cell cycle216. Mitogens and cell
adhesion to ECM control the progression through the G1 phase of the cell cycle, by
modulating the expression and protein levels of the cyclins and cyclin dependent
kinases217.
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Figure 1.1 Model for HA involvement in tumor biology. HA produced by tumor cells
influences tumor cell proliferation and motility. HA is degraded by the enzyme
hyaluronidase and other mediators such as reactive oxygen species (ROS), hypoxia and
also due to necrosis to form small polymers or oligosaccharides. This processing may be
initiated extracellularly by Hyal1 and/or Hyal2 and continued intracellularly following
endosomal uptake by cell surface HA receptors. Disruption of HA polymer/receptor
ligation (RHAMM, CD44) by exposure to HA oligos may trigger signaling in tumor cells
to initiate proliferation and motility, but also in endothelial cells to promote angiogenesis
(Figure courtesy from Dr. Melanie A. Simpson).
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The key molecules that govern the various steps of cell cycle progression include
the cyclin dependent kinases (CDK), CDK regulators such as cyclins which are the
activators of CDKs and Cyclin Kinase Inhibitors (CKIs) which inhibit the activity of the
CDKs. The CDK substrates in G1 are members of the retinoblastoma (Rb) protein
family218. The CDKs are serine/threonine kinases activated by cyclin binding to
phosphorylate the Rb proteins. CDK4 and CDK6 form active heterodimeric complexes
with the D-type cyclins (cyclin D1, D2 and D3). CDK2 is activated by binding to the Etype cyclins during the G1/S transition and the A-type cyclins during the S phase.
Collectively, these CDK proteins control the transition from G1 to S phase (Figure 1.2).
There are two classes of CKIs: the Cip/Kip family and the INK family (INhibitors
of Kinases). The Cip/Kip proteins p21cip1 (p21) and p27kip1 (p27) mainly inhibit
CDK2219,220. The CKI p21 acts both by inhibiting CDK2 activity and also by inhibiting
PCNA, an elongation factor for DNA polymerase δ, thus overall inhibiting progression
through S-phase. At low concentrations, Cip/Kip proteins promote CDK4 kinase activity
through the stabilization cyclinD/CDK4 complex. At higher concentrations of CKI,
however, CDK4 activity is inhibited221. INK4 family proteins p16INK4a (p16),
p15INK4b (p15), p18INK4c (p18), and p19INK4d (p19) function by inhibiting the CDK4
and CDK6 – cyclin D1 complex214,222-224.
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Figure 1.2 Regulation of cell cycle progression via growth factor/ERK signaling.
ERK is activated in response to growth factors. The cell cycle consists for the DNAsynthetic phase (S-Phase) and the cell division phase (Mitotic phase-M phase). These are
interspersed by the G1 and G2 gap phases. Activated ERK stimulates expression of
immediate early genes such as AP-1. Subsequently this induces expression of cyclin
D(cyclin D1.2.3). The cyclin D-CDK4/6 complex then initiates retinoblastoma (Rb)
phosphorylation, which activates E2F family of transcription factors and induces
expression of target genes such as cyclin E. The cyclin E-Cdk2 further enhances
phosphorylation of Rb and promotes the S-phase entry. The activation and function of the
cyclin-Cdk complexes are further regulated/inhibited by the p21cip (p21) and p27kip (p27)
family of cyclin dependent kinase inhibitors (Adapted from242).
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1.7.1

Growth Factors and Cell Cycle Progression
Growth factors bind to their cognate receptors on the cell surface, and mediate

signaling cascades that influence phosphorylation of ERK1/2. Growth factor receptors
have intrinsic tyrosine kinase activity in their cytoplasmic tail. On binding to growth
factors, the receptors are autophosphorylated, which allows docking of SH2-domain
containing adaptor proteins such as Shc and/or Grb2, and activation of the
Ras/Raf1/MEK/ERK1/2 pathway225-227 (Figure 1.3). Several intracellular pathways are
activated to promote cell proliferation. For instance EGF and PDGF are capable of
rescuing serum starved fibroblasts from G0 arrest by initiating proliferation. This occurs
predominantly through the Ras/Raf/MEK/ERK pathway, but also through PI3-kinase.
Activated ERK1/2 translocates to the nucleus, phosphorylates the transcription factor
Elk-1, which is linked to the expression of cyclin D1228,229. There is extensive evidence to
show that integrin mediated signaling can influence growth factor signaling via this
cascade to control cell proliferation56,230.
Fibroblasts and epithelial cells depend on integrin-mediated adhesion and its
consequent signaling for translation of cyclin D1, expression of cyclin A and
downregulation of p21 and p27217,231-233. The dual requirement of integrins and growth
factors for cell cycle progression originates predominantly with the sustained activation
of the mitogen-activated protein kinases ERK1/2. It has also been shown that other
pathways triggered through PI3K and Rho family GTPases also regulate cyclin D1
expression234,235. Rac signaling to cyclin D1 requires NF-κB and results in earlier
expression of cyclin D1 within G1 phase236,237.
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Figure 1.3 ERK activation by growth factors by the Ras/Raf/MEK pathway. Growth
factor (GF) binds to its receptor (GF receptor). Autophosphorylation (Y-p) of the receptor
on GF binding causes initiation of a cascade involving adaptor proteins Grb2, Sos, and
Ras. Activated Ras binds to Raf activating it. Activating Raf in turn activates MEK and
culminates in the activation of ERK and translocation to the nucleus. ERK further
phosphorylates transcription factor Elk and this causes transcription of immediate early
genes (IEG). (Modified from231,242).
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1.7.2

Hyaluronan and Cell Cycle Progression
HA plays a role in both proliferative and anti-proliferative responses in a size and

dose dependent manner. This suggests that HA can influence cell cycle progression to
elicit its effect on cell proliferation. Endogenous CD44-HA interaction has been shown to
be necessary for constitutive activation of the ERBB2 receptor in colon and mammary
carcinoma cells173 and also general activation of a number of other growth factor
receptors such as EGFR, PDGFR-β, IGFR-β both in a ligand dependent and independent
manner238. Constitutive engagement of CD44 with small quantities of newly synthesized
HA results in assembly of signaling complexes containing PI3-K, ezrin, and cdc37173.
This property of HA might be a signal for cell cycle progression in coordination with the
growth factor signaling pathway. It has been proposed that HA polymer binding to CD44
antagonizes mitogen induced S-phase entry by inhibiting the mitogen dependent cyclin
D1 induction and downregulation of p27 in vascular smooth muscle cells239,240. The
membrane proximal signaling associated with such changes is not understood, but it is
intriguing to speculate that its effect might be due to differential association of CD44
with cytoskeletal signaling components such as ezrin or merlin or due to altered
interaction with growth factor receptors.
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1.8

RESEARCH GOALS
Accumulation of HA in patient prostate tumors together with elevated expression

of Hyal1 is an independent prognostic indicator of CaP progression and poor outcome for
patients14,15,241. This clinical correlation is consistent in studies which have suggested the
HA plays an active role in mediating biologic processes such as cell proliferation and
migration. For instance aggressive CaP cells show upregulation of HAS2 and HAS3 and
inhibition of these enzymes causes impaired tumor growth and vascularization164 and
overexpression of HAS has been shown to promote tumorigenesis in many systems160-163.
Hyal1 overexpression has also shown to promote tumor growth and metastasis176,183, but
the exact molecular mechanism for tumorigenesis has not been elucidated. Hyal1 could
potentially act indirectly by generating HA oligomers some of which has potent biologic
function such as that in angiogenesis94. Studies have shown that HA oligomers are
angiogenic and induce growth and recruitment of endothelial cells, whereas large HA
polymers are anti-proliferative, and extremely small fragments of HA are
apoptotic174,204,206,209. Moreover, Hyal1 could also directly promote tumorigenesis by
autocrine effects on the tumor cell and presence of HA might be required for optimum
effect of Hyal. This has been demonstrated, in glioma cells where, excess production of
HA is tumorigenic only in the presence of Hyal91. This suggests that the outcome of HA
metabolism in tumor progression could vary depending on the differential expression of
the HA biosynthetic and processing enzymes. Studies examining the combined roles of
HAS and Hyal1 in prostate tumor progression are largely unavailable. Thus there is a
need for systematic assessment of roles of HA biosynthesis and turnover in prostate
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tumor biology, particularly with respect to the molecular principles governing tumor
progression and to determine the chronological role of HA in CaP development.
The primary research goal of this project was to evaluate the concerted effect of
HAS and Hyal in prostate tumor biology, with particular emphasis on tumor growth,
angiogenesis and metastasis. The eventual goal will be to identify novel molecular
pathways underlying the phenotypic differences due to altered HA metabolism, thus
charting the path for development of biomarkers for CaP diagnosis, and new targets for
therapeutic strategies.

1.9

APPROACH AND OVERVIEW OF CHAPTERS 2-4
The first approach we took to address the hypothesis was to identify a suitable

prostate tumor cell line, which expresses negligible or low levels of endogenous HAS and
Hyal. Systematic screening of various available prostate cancer cell lines identified the
non-metastatic 22Rv1 prostate cancer cell lines for our studies. We developed stable cell
lines constitutively expressing the HAS2/3, Hyal1 and co-expressing HAS2/3 and Hyal1
in the 22Rv1 cell lines. These cell lines were evaluated in vitro for the transgene
expression, and for tumorigenic properties such as intrinsic growth rate and ECM
adhesion. We additionally developed a tetracycline-inducible system to directly evaluate
the correlation between HA production and tumor cell growth in vitro. Subsequently
studies were done in subcutaneous mouse models to test the effect on tumor growth and
angiogenesis (Chapter 2). Since, a true picture of tumorigenesis and metastasis of these
transfectants can only be obtained in relevant prostate microenvironment, we tested these
Hyal1/HAS transfectants in orthotopic prostate models. The transfectants were
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characterized for the tumorigenic, angiogenic and metastatic properties in vivo and
further to that we obtained a mechanistic correlation in vitro for tumor cell cycle
progression (growth), adhesion and motility (metastasis) (Chapter 3). We further
characterized growth factor mediated effects on ERK activation in cells expressing Hyal1
and HAS3. We also carried out methodical characterization of the various cell cycle
regulatory proteins to illuminate the underlying mechanism for altered cell cycle kinetics
and tumorigenesis in the Hyal1 and HAS transfectants (Chapter 4).
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CHAPTER 2

INDUCIBLE HYALURONAN PRODUCTION REVEALS DIFFERENTIAL EFFECTS ON
PROSTATE TUMOR CELL GROWTH AND TUMOR ANGIOGENESIS

Note: This chapter has been published. The authors are Alamelu G. Bharadwaj,
Katherine Rector and Melanie A. Simpson. The animal work presented in this chapter
was carried out by Dr. Melanie A. Simpson.
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2.1

ABSTRACT
Prostate cancer progression can be predicted in human tumor biopsies by

abundant hyaluronan (HA) and its processing enzyme, the hyaluronidase Hyal1.
Accumulation of HA is dictated by the balance between expression levels of HA
synthases, the enzymes that produce HA polymers, and hyaluronidases, which process
polymers to oligosaccharides. Aggressive prostate tumor cells express 20-fold higher
levels of the hyaluronan synthase HAS3, but the mechanistic relevance of this correlation
has not been determined. We stably overexpressed HAS3 in prostate tumor cells.
Adhesion to extracellular matrix and cellular growth kinetics in vitro were significantly
reduced. Slow growth in culture was restored either by exogenous addition of
hyaluronidase or by stable Hyal1 coexpression. Coexpression did not improve
comparably slow growth in mice, however, suggesting excess hyaluronan production by
HAS3 may alter the balance required for induced tumor growth. To address this, we used
a tetracycline inducible HAS3 expression system in which hyaluronan production could
be experimentally controlled. Adjusting temporal parameters of hyaluronan production
directly affected growth rate of the cells. Relief from growth suppression in vitro but not
in vivo by enzymatic removal of HA effectively uncouples the respective roles of
hyaluronan in growth and angiogenesis, suggesting growth mediation is less critical to
establishment of the tumor than early vascular development. Collectively, results also
imply that HA processing by elevated Hyal1 expression in invasive prostate cancer is a
requirement for progression.
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2.2

INTRODUCTION
Despite improved detection and diagnosis of prostate cancer, this disease remains

the second leading cause of malignant mortality in U.S. males1,2. Metastasis may occur
with no prior indication of an invasive tumor3, so prostate cancer progression is difficult
to predict. Changes in levels of extracellular matrix molecules such as hyaluronan (HA),
a high molecular weight polysaccharide, and its processing enzyme, the hyaluronidase
Hyal1, within the prostate extracellular matrix have been correlated to invasive prostate
cancer progression4-11. The molecular mechanisms underlying this correlation could
provide important insights for therapeutic development or improved diagnosis of prostate
cancer.
HA production is a tightly regulated process that impacts cellular transformation
and motility during development12-14. Dynamic HA turnover within tissues controls many
acute processes such as wound healing or immune function. HA accumulation is the
outcome of a balance between the activity of HA synthases (HAS), enzymes that
synthesize the linear polymers15, and hyaluronidases, which process the polymers to
biologically potent oligosaccharides16. Excess quantities of large HA polymers have been
reported to suppress cellular growth17,18 and angiogenesis19,20, whereas processed
oligosaccharides

dramatically

stimulate

angiogenesis21-23

and

fully

degraded

oligosaccharides induce apoptosis14,24,25. HAS isozymes (HAS1, HAS2 and HAS3) have
been overexpressed in several tumorigenic cell lines, and may impact tumor growth
kinetics in a dose dependent fashion26. For example, relatively low overexpression of
HAS2 augments tumorigenesis, while high levels of HAS2 expression either have no
effect or suppress growth of subcutaneous tumors. Interestingly, a similar effect was
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recently shown for the hyaluronidase Hyal15, originally identified as a tumor suppressor27
despite its subsequent direct correlation with cancer5,8,28. HA turnover is intricately
orchestrated by the hyaluronidases Hyal1 and Hyal229-31, in conjunction with the HA
receptor CD4432,33. Hyal1 is secreted and deposited to the extracellular space, where it
may be retained non-covalently by binding to HA30. Hyal2 is GPI-anchored at the cell
surface, localized to microdomains with CD4434, stimulation of which signals HA uptake
subsequent to its initial extracellular processing by Hyal1/2. Hyal1 exhibits maximal
activity at acidic pH, while Hyal2 is active in both acidic and neutral conditions,
consistent with intracellular lysosomal function of both enzymes upon internalization35,36.
However, presence of locally acidic microdomains at individual cell surfaces34 and within
rapidly developing tumors37,38 may promote inappropriate activation, particularly of
Hyal1, in the extracellular compartment. Differential hyaluronidase activity may thereby
translate to a gradient of angiogenic and apoptotic oligosaccharides. The importance of a
balance between expression levels of HA biosynthetic and processing enzymes for tumor
cell growth is further suggested by the finding that HAS2 overexpression may promote
growth in cell types with significant hyaluronidase activity, while it inhibits growth of
cells lacking hyaluronidase39.
We have previously shown that aggressive prostate tumor cell lines secrete excess
HA and retain it at the cell surface in large matrices, a property that differentially
mediates the interaction of the tumor cells with stromal and epithelial cell types40,41.
Production of excess HA by prostate tumor cells is catalyzed by elevated levels of HAS2
and HAS3, specifically in aggressive cells. Inhibition of HAS expression in these cells
interferes with tumorigenesis, angiogenesis and metastasis, so the HA product clearly has
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a role in these processes in a prostate tumor model41. When we coexpressed HAS2 and
Hyal1 in stable tumor cell lines, resultant subcutaneous tumor sizes were 2-3-fold larger
than those arising from either HAS2 or Hyal1 individually transfected cells42, suggesting
combined production and processing of HA contribute synergistically to tumor growth
mechanisms.
Since HAS3 is the most dramatically upregulated isozyme in metastatic prostate
tumor cells, we reasoned that its upregulated expression would have a demonstrable
influence on HA matrix production and sought to test the functional relevance of this
correlation. We report here the first overexpression of HAS3 in prostate tumor cells.
Stable lines were selected for HAS3 overexpression or for Hyal1/HAS3 coexpression to
assess the respective outcomes in mice. Since HAS3 overexpression suppressed
tumorigenesis, we additionally developed a tetracycline inducible system for HAS3
overexpression and directly evaluated the correlation between HA production and
prostate tumor cell growth in vitro. Our findings support a model in which excess HA
suppresses tumorigenesis by diminishing apparent cellular growth and limiting
angiogenesis. Hyal1 is thus implicated in promotion of angiogenesis by dissipation of
accumulated HA within tumors, which may facilitate its recognition as an angiogenic
signal.
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2.3

MATERIALS AND METHODS

2.3.1

Cell Culture, Materials, and Reagents
22Rv1 human prostate adenocarcinoma cells43 were purchased from ATCC and

maintained in RPMI-1640 medium containing 10% fetal bovine serum. Selection,
characterization and maintenance of 22Rv1 stable transfectants in standard medium
containing 1.25 mg/ml G418 has been previously described42. The pIRES2-EGFP vector
and plasmids pTet-ON and pTRE-Tight that comprise the tetracycline-inducible
mammalian expression system were obtained from Clontech (Mountain View, CA).
Doxycycline and Tet System approved fetal bovine serum were also from Clontech. AntiFlag antibody was purchased from Stratagene (La Jolla, CA). Collagens I and IV were
from BD Biosciences (San Jose, CA). Fibronectin, laminin and calcein-AM were from
Invitrogen (Carlsbad, CA) and antibodies to alpha and beta integrins were from
Chemicon

(Temecula,

CA).

Human

umbilical

cord

HA,

alcian

blue

and

tetramethylbenzidine were from Sigma (St. Louis, MO). Streptomyces hyaluronidase was
purchased from Calbiochem (EMD Biosciences, San Diego, CA). Biotinylated HA
binding protein (bHABP) was from Seikagaku (Associates of Cape Cod, East Falmouth,
MA).

2.3.2 Transfection and Stable Selection of Prostate Tumor Cells
The plasmid constructs encoding Flag epitope-tagged Hyal1 or HAS3 were
previously described41,42. 22Rv1 human prostate tumor cells were transfected with: 1)
vector alone (pIRES2-EGFP), 2) plasmid encoding Hyal1-Flag, 3) HAS3-Flag plasmid,
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or 4) both the Hyal1 and the HAS3 plasmid constructs. Liposome-mediated transfection
with FuGene6 reagent (Roche Diagnostics, Indianapolis, IN) was performed according to
the manufacturer’s protocol. Gene expression was verified by western blot, and by
enzyme activity assays as described. Stable 22Rv1 transfectants were obtained by clonal
isolation following incubation for 14-20 days with G418 (1.25 mg/ml). Multiple clones
were tested for expression and those with average levels of expression were pooled to
eliminate the bias from isolated selection. Once established, stable transfectants were
maintained in the selection medium.

2.3.3

Western Analysis of Transgene Expression
Conditioned media from cells cultured in 10 cm plates were prepared for western

analysis by diluting 1:1 with SDS gel-loading buffer and boiling for 5 min. To prepare
whole cell lysates, cultured cells were washed with PBS and lysed by addition of 0.5 ml
of hot SDS gel-loading buffer. Cellular lysates were homogenized by shearing through a
26-gauge needle, incubated at 37˚C for 20 min and centrifuged. All samples were
normalized for protein content or cell number as indicated. Equal amounts of each sample
were separated by SDS-PAGE and transferred to Immobilon-P membrane. After
blocking, membranes were probed with anti-Flag M2 or anti-VP16 antibody as
appropriate

(2

μg/ml)

and

blotted

proteins

were

detected

by

enhanced

chemiluminescence. For densitometric analysis, samples loaded in triplicate were blotted.
Western blots were scanned and converted to grayscale in Adobe Photoshop. Pixel
density in identically sized regions encompassing each band was used to calculate the

72
mean ± SEM for expression levels in Hyal1/HAS3 cotransfectants relative to HAS3
transfectants.

2.3.4

Hyaluronidase Activity Assays
Overnight conditioned media from stably transfected cell lines were concentrated

ten-fold and electrophoresed by SDS-PAGE on a 12% polyacrylamide gel containing 0.2
mg/ml HA. After a 1 h incubation at room temperature in 3% Triton X-100, the gel was
placed in hyaluronidase assay buffer (50 mM sodium formate, pH 4.0, 150 mM NaCl,
0.1% BSA) at 37˚C overnight. Hyaluronidase activity was detected as a clear band at the
expected molecular weight for Hyal1 upon staining 1 h with 0.5% alcian blue and
destaining with 7% acetic acid. Cell lysates were assayed similarly and although several
light bands were visible, no significant differences were observed between control and
Hyal1 transfected cells indicating the majority of overexpressed Hyal1 was secreted.
To quantify hyaluronidase activity, we used a microplate assay essentially as previously
described6. Briefly, serial dilutions of concentrated conditioned media normalized for
protein content were applied in triplicate to HA-precoated microwell plates. Following a
1 h incubation in hyaluronidase assay buffer, wells were washed and developed with
biotinylated HABP, followed by avidin-biotin HRP with tetramethylbenzidine substrate.
Absorbance at 650 nm was used to interpolate specific activity from a concurrent
Streptomyces hyaluronidase standard curve. In competition assays, exogenous HA
(average MW of ≈20 kDa, Lifecore, Chaska, MN) was included in the 1 h plate
incubation.

73
2.3.5

HA Quantification
HA content of transfected cell culture supernatants was determined by

competitive binding assay6,44,45. Overnight conditioned media from prostate tumor cell
cultures were harvested and cells counted. Equal volumes of serially diluted media were
combined with biotinylated HABP (0.5 μg/ml), and incubated in HA-precoated microtiter
plates

for

6-8

h.

Plates

were

developed

using

avidin-biotin

HRP

with

tetramethylbenzidine as substrate, and absorbance was read at 650 nm. HA concentration
was interpolated from a standard curve and normalized to cell number.

2.3.6

HA Pericellular Detection and Quantification
Pericellular HA retention was visualized and quantified by particle exclusion as

described previously41,45. Briefly, cell cultures were incubated with 2 mg/ml aggrecan
followed by addition of 1x108 fixed red blood cells. After 15 min, cells were viewed with
phase-contrast microscopy and digitally photographed at 400x magnification. Matrix
retention was quantified using Adobe Photoshop to calculate relative areas for matrices
and cellular boundaries of individual cells. HA matrix thickness is presented as the ratio
of matrix area to cell area for each transfectant or condition.

2.3.7

Growth Assays
Two-dimensional growth in culture was assayed as previously described45.

Equivalent passages of each tumor cell line were plated at 5000 cells/well in 24-well
plates. At 24-hour intervals, quadruplicate wells of each cell line were released with
trypsin, neutralized, and manually counted in a hemacytometer. Duplicate counts for each
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well were averaged to obtain the total cell count per well. Each point is the mean ± SEM
of the total cell counts. Though the graph presents data from a single assay in
quadruplicate, the growth trends were reproduced in three additional identical assays.

2.3.8

Mouse Subcutaneous Injection
All mice were cared for and maintained under the supervision and guidelines of

the University of Nebraska-Lincoln IACUC Committee. Male NOD/SCID mice (Jackson
Labs) (8 animals per condition) were injected subcutaneously in each flank with 1x106
tumor cells suspended in 100 μl of serum-free RPMI. After 28 days, mice were sacrificed
and tumors were dissected and weighed. Mean tumor wet weight ±SEM was plotted for
each cell line. Statistical significance was assigned by Student’s two-tailed t-test. The
experiment was repeated with an additional 8 animals per cell line and similar results
were obtained.

2.3.9

Immunohistochemistry and Immunofluorescence
HA content and vascularization of tumors were detected as described

previously41. Briefly, after weighing, tumors were divided in halves. One half was
formalin fixed and embedded in paraffin. The other half was snap frozen in OCT
compound. For HA detection, paraffin-embedded tumors were sectioned, dewaxed,
probed with biotinylated HABP and developed using the Vectastain ABC kit (Vector
Laboratories, Irvine, CA). Sections were counterstained with Meyer’s hematoxylin to
visualize cellular boundaries. White light images were collected at 200x magnification.
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Vascularization of the tumors was assessed in ethanol fixed frozen sections (8

m

thickness) by antibody staining for CD31 as described previously41,46.

2.3.10 Angiogenesis Quantification
CD31-phycoerythrin conjugated antibody staining of frozen sections was
visualized by fluorescence microscopy. Five random sections from each of three tumors
per cell line were digitally photographed with 5 s exposure time. Images saved as TIF
files were converted from 16 bit to 8 bit in Adobe Photoshop, red channel fluorescence
was isolated, images were converted to grayscale, inverted, and a black-and-white
threshhold was arbitrarily set based on levels. The histogram function was used to
determine vessel density as represented by density of black pixels at 0 on the black-towhite scale. Average pixel density for each transfectant tumor section was normalized to
the average pixel density for untransfected tumor sections. Statistical significance was
assigned by Student’s two-tailed t-test.

2.3.11 Extracellular Matrix Adhesion and Blocking
Microplates were precoated with collagen I, collagen IV, laminin or fibronectin in
serially diluted doses for 1 h at 37˚C and blocked with 3% BSA. Subconfluent cells were
released with 1 mM EDTA, washed and resuspended in adhesion medium (serum-free
RPMI 1640 containing 20 mM HEPES, pH 7.4, and 1% BSA), and labeled with calceinAM (25 µg/106 cells, 20 min at 37˚C). Labeled cells (104 cells/well) were incubated in
quadruplicate wells of the precoated plates for 2 h at 37˚C. Non-adherent cells were
removed with three gentle washes in adhesion medium. Remaining adherent cells were
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lysed with 0.2N NaOH containing 1% SDS. Fluorescence was measured in a microplate
spectrophotometer and the percentage of adherent cells relative to the input number was
calculated from a standard curve of each labeled cell culture. For adhesion specificity
tests, cells were preincubated with antibodies against integrins β1, α1, α2, or α5 (5 µg/ml)
for 10 min at 37˚C prior to placing them in the substrate-coated microplates. Antibodies
were present throughout the assay incubation.

2.3.12 Generation and Characterization of Tet-inducible 22Rv1 Cells
22Rv1 cells were transfected with pTet-ON using FuGene6 reagent and selected
with 1.5 mg/ml G418 until isolated colonies were obtained. Individual colonies were
amplified in the continuous presence of G418 and screened for expression of the
tetracycline transactivator-VP16 fusion protein by western blots probed with anti-VP16
antibody. VP16 positive clones were then tested for inducible gene expression by
transient transfection with a GFP or luciferase reporter plasmid. Transfectants were
induced by applying media containing 2 μg/ml doxycycline (dox) and digitally
photographed or harvested to prepare soluble extracts 48 h later. To characterize HAS3
expression, transient transfectants were initially induced with dox for 48 h, at which time
conditioned media were assayed for HA content as described above and membrane
enriched fractions were harvested by mechanical disruption and solubilization in 1%
Triton X-100 for western blotting. In subsequent experiments, control and HAS3
transient transfectants were induced with dox 24 h after transfection and plated (20,000
cells/well) for simultaneous assays of growth rate, HA content and HAS3 expression as
indicated in specific figures. In some experiments, exogenous Streptomyces
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hyaluronidase (0.2 mU/ml final concentration per dose) was added daily throughout the
time course. To assay the temporal effects of HA induction, transfectants (20,000
cells/well) were plated and induced identically but dox was removed after day 4. At that
time, all media were removed and replaced with fresh media. In additional experiments,
cells were identically plated and assayed, but dox was not added until day 4, at which
point all standard media were removed and replaced.

2.4

RESULTS

2.4.1 Stable Expression of HAS3 and Hyal1
We previously characterized HAS and hyaluronidase isozyme expression and
activity in 22Rv1 cells42. HAS3 was expressed at basal levels comparable to normal
prostate and synthesized relatively little HA. Though RT-PCR indicated expression of
Hyal1 message, its enzymatic activity was very low in comparison with that of Hyal1
transfectants. Since our goal was to determine the respective and concerted functions of
Hyal1 and HAS3, 22Rv1 cells were deemed an appropriate model in which to
overexpress these enzymes.
Stable lines were selected for overexpression of Flag epitope tagged Hyal1 or
HAS3 from a constitutive eukaryotic promoter in the pIRES2-EGFP bicistronic reporter
vector. Hyal1/HAS3 cotransfectants were identified that expressed approximately
equivalent levels of Hyal1 with respect to the individual Hyal1 transfectants. Conditioned
media from each transfectant were compared by western blot to the vector control (Figure
2.1A) to verify similar expression levels. Corresponding activity of Hyal1 in the control
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(lane 1), Hyal1 (lane 2), and Hyal1/HAS3 (lane 3) conditioned media was initially
measured by HA substrate gel electrophoresis (Figure 2.1B). As expected, the control
media contained very little hyaluronidase activity, while activity in the Hyal1 transfectant
and cotransfectant media (lanes 2 and 3) was significantly increased. We then assayed
serial dilutions of transfectant conditioned media in a quantitative microplate assay.
Interestingly, though the specific activity of Hyal1 transfectant media was constant at all
dilutions, the specific hyaluronidase activity of Hyal1/HAS3 media increased with
dilution (Figure 2.1C). Thus, the Hyal1 activity in these cells was underestimated at the
lower dilutions and its increasing specific activity implied the dilution of an inhibitor or a
competitor. We postulated that HA produced in the media by concurrent expression of
HAS3 could be competing with HA immobilized on the microplate and artificially
reducing the apparent activity of Hyal1. To confirm this, we added two different
concentrations of exogenous HA (MW ≈20kDa) to the Hyal1 microplate assays (Figure
2.1D). At the endpoint, we measured the remaining HA content of the solution and
plotted it as a fraction of exogenous HA added. Hyal1 activity was calculated from the
amount of HA remaining on the plate and plotted as a fraction of the activity measured in
the absence of exogenous HA (white bar). Though the enzyme is clearly active,
degrading both solubilized and immobilized HA, its apparent activity in the microplate is
significantly competed by inclusion of excess HA. These results are consistent with HA
content of the Hyal1/HAS3 media reducing the measured Hyal1 specific activity.
Nonetheless, using the 1:50 dilution data shown in Figure 1C we estimate that Hyal1
activity of the Hyal1/HAS cells is only ≈1.75-fold higher than that of the Hyal1 cells.
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Figure 2.1 Constitutive expression and activity of Hyal1. (A) Western blot of
conditioned media from 22Rv1 cells stably selected for expression of control vector
(GFP, lane 1), Hyal1 alone (lane 2), or Hyal1 and HAS3 concurrently (lane 3) probed
with anti-Flag M2 antibody. Hyal1 was detected as a single band of ≈60 kDa. (B) Hyal1
activity of GFP, Hyal1, and Hyal1/HAS3 stable transfectants was assayed by HA
substrate gel. Concentrated conditioned media were normalized to cell number and
electrophoresed in a HA-containing polyacrylamide gel. After an overnight incubation,
areas of Hyal1 activity were revealed as clear bands upon staining with alcian blue and
destaining with acetic acid. (C) Hyal1 activity of transfectant conditioned media was
quantified by microplate assay and compared in serial dilutions. The mean ± SEM of
triplicate determinations is plotted in mU/ml/mg protein. * p<0.01 relative to the 1:5
dilution values (white bar). (D) Hyal1 activity was assayed by microplate in the presence
or absence of exogenous ≈20kDa HA in the indicated amounts. Fraction of input HA
degraded is indicated (left bars). * p<0.01 relative to HA 0 mg/ml (white bar).
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Since HA is synthesized at the plasma membrane and concurrently secreted to the
extracellular space, HAS3 activity was verified in the stable lines by quantifying HA in
conditioned media and at the cell surface. Stable HAS3 transfectants produced > 30-fold
more HA than control GFP or Hyal1 transfected cells (Figure 2.2A). Hyal1/HAS3
cotransfectant media contained ≈ 9-fold more HA than controls. Expression levels of
HAS3 were compared by western blot of whole cell lysates probed for the Flag epitope
(Figure 2.2A, inset). Triplicate determinations of each of the three lysates showed that the
Hyal1/HAS3 cotransfectants (representative sample in lane 3) expressed 69±3.1% of the
HAS3-Flag quantity detected in single HAS3 transfectants (lane 2). Thus, the HA content
of Hyal1/HAS3 cultures was only 30% of the HAS3 culture HA content, less than half of
what would be expected from the comparable HAS3 protein level. This result suggests
Hyal1, present in the media of the cotransfected cells, either processes HA as it is
synthesized or facilitates its removal from the media. Particle exclusion analysis of
surface HA showed significant HA retention by the HAS3 transfected cells (Figure 2.2C).
Hyal1/HAS3 cotransfectants retained additional HA relative to GFP transfected controls
(compare Figure 2.2, panels D and B, respectively). Matrix and cell boundaries were
traced in digital images to quantify average cellular HA retention (Figure 2.2E). Results
are consistent with HA accumulation in the media. Collectively, these data confirm both
HAS3 and Hyal1 activities are significant in cotransfectants.
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Figure 2.2 Expression and activity of HAS3 in stable transfectants. (A) Stable
transfectants of 22Rv1 cells were compared for expression and activity of HAS3 by
western blot and quantification of secreted HA. The inset panel shows a western blot of
lysates from control GFP (lane 1), HAS3 transfectants (lane 2) or Hyal1/HAS3
cotransfectants (lane 3) probed with anti-Flag antibody. HA content of conditioned media
was determined by competitive binding assay as described in Experimental Procedures. *
p<0.01 relative to GFP. Cell surface retention of HA was evaluated by particle exclusion
assay as described. Representative images from at least 20 individual cells of each type
acquired at 400x magnification are shown: (B) control GFP; (C) HAS3; (D)
Hyal1/HAS3. Inset panels illustrate GFP reporter fluorescence of the cells photographed.
(E) Individual matrix and cellular boundaries were traced in Adobe Photoshop on the
digital images and used to calculate respective areas. Thickness of pericellular HA is
plotted as a matrix:cell area ratio.
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2.4.2

HAS3 Decreases Subcutaneous Growth and Vascular Density of Prostate

Tumor Xenografts
To assay the effects of HAS3 and Hyal1 overexpression in prostate tumorigenesis,
we injected stable 22Rv1 transfectants subcutaneously in flanks of NOD/SCID mice.
Tumor growth was monitored over a period of 4 weeks, at which time mice were
sacrificed and tumors were excised for analysis. Comparison of the mean tumor wet
weight shows essentially identical growth of control and Hyal1 transfectants (Figure
2.3A). However, both HAS3 and Hyal1/HAS3 transfectants yielded ≈ 40% smaller
tumors than GFP controls. Since we previously found that Hyal1 overexpression
increased angiogenesis within subcutaneous tumors, we analyzed all tumors for vessel
density by staining tumor sections for CD31, a blood vessel endothelial cell surface
marker (Figure 2.3B). As expected, Hyal1 transfectant tumors were approximately 2-fold
more vascular than controls. Vessel density of HAS3 tumors was 62% of controls,
consistent with the extent of reduction in tumor size. Although tumor size did not change
appreciably between the HAS3 and Hyal1/HAS3 transfectant tumors, vascularization of
the cotransfectants was not statistically different from controls. This result suggests
Hyal1 expression may compensate for suppression of angiogenesis by HAS3.
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Figure 2.3 Effect of constitutive HAS3 expression on subcutaneous growth and
vascularization of prostate tumors in mice. Stable transfectants of 22Rv1 selected for
constitutive expression of control GFP, Hyal1, HAS3, or Hyal1/HAS3 coexpression were
injected subcutaneously (1x106 cells per injection) into flanks of male NOD/SCID mice.
After 28 days, animals were sacrificed and tumors were excised, weighed and sectioned
for analysis. (A) Tumor size is plotted as mean tumor wet weight ± SEM of 8 animals per
group. Statistical values are indicated. (B) Vascular density of tumors was determined by
digital analysis of anti-CD31 antibody staining in cryopreserved sections. Each value
represents the mean ± SEM of 15 digital images from 3 tumors per group normalized to
values in control tumors. (C-F) HA was detected in formalin-fixed tumor sections using
biotinylated HABP, followed by streptavidin-HRP conjugate and diaminobenzidine
precipitation. Cells were counterstained with hematoxylin. Representative sections from
each tumor type photographed at 400x magnification are shown: (C) GFP; (D) Hyal1; (E)
HAS3; (F) Hyal1+HAS3.
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To determine if there was a correlation between HA levels and suppression of
tumor growth, HA content of the tumors was determined histologically in formalin-fixed
sections. Virtual absence of HA, visualized as a brown precipitate among the purple
hematoxylin counterstained cells, was evident in control GFP and Hyal1 transfectant
tumors (Figure 2.3, panels C and D). The tumors arising from HAS3 transfectants
exhibited extensive accumulation of pericellular HA (Figure 2.3E). HA was detected
throughout Hyal1/HAS3 cotransfectant tumor sections, though not localized entirely in
the pericellular space (Figure 2.3F). Thus, significant HA deposition in the tumors
correlated with suppression of tumor growth. Concurrent expression of Hyal1 was not
sufficient to eliminate HA accumulation in these tumors.

2.4.3

HAS3 Overexpression Diminishes Intrinsic Growth Rate and Adhesion to

Extracellular Matrix
To address the mechanisms of reduced tumor growth upon HAS3 overexpression,
we first assayed growth kinetics of the stable transfectants in culture. Quadruplicate wells
plated with equal numbers of cells in suspension were counted manually each day for
seven days (Figure 2.4). Growth rate of HAS3 transfectants (filled circles) was >60%
slower than that of controls (filled squares). Interestingly, cotransfectants expressing both
Hyal1 and HAS3 (open circles) grew at identical rates to controls. Inclusion of exogenous
HA in the culture media of control or cotransfected cells throughout the assay had no
effects on growth (not shown). These observations are similar to previously reported
growth kinetics of HAS2 transfected and cotransfected cells42. Thus, presence of
hyaluronan in excess reduces growth rate specifically of cells that are synthesizing it.
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Figure 2.4 Growth kinetics of stable transfectants in culture. Equal numbers of 22Rv1
cells stably selected for constitutive expression of control GFP (squares), HAS3 (filled
circles), or Hyal1+HAS3 (open circles) were plated in 24-well plates. Quadruplicate
wells of each cell line were trypsin released and manually counted each day for 7 days. *
p<0.01 for HAS3 values (filled circles) relative to GFP values (filled squares).
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Many adherent cell types, including tumorigenic lines derived from epithelial
cells (i.e.; 22Rv1), are dependent upon engagement of cell adhesion receptors for survival
and growth47. Impairment of adhesion in anchorage dependent cells leads to anoikis48,
and apparent reduction in growth kinetics. Since hyaluronan accumulation at the cell
surface has the potential to influence cell surface interactions physically, we investigated
anchorage dependence of our stable transfectants by assaying adhesion to extracellular
matrix (ECM) proteins commonly found in basement membranes and connective tissue.
Tumor cell suspensions were first incubated in 96-well plates coated with type IV
collagen (Col IV) or fibronectin (FN). While Hyal1 alone did not alter adhesion to these
substrates, HAS3 transfectants were 45% less adherent to Col IV and 90% less adherent
to fibronectin relative to the GFP control cells (Figure 2.5A). Importantly, Hyal1/HAS3
cotransfectants exhibited control adhesion levels. Reduced adhesion of HAS3 cells by
>90% was observed when assayed on Type I collagen, the major component of
subcutaneous connective tissue, and laminin (Figure 2.5B, gray bars). Reduced adhesion
was not due to retention of HA at the cell surface during the assays, because adhesion
was not restored when exogenous hyaluronidase was included (Figure 2.5B, dark bars).
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Figure 2.5 Adhesion to extracellular matrix proteins is compromised by stable
HAS3 overexpression. Single cell suspensions were calcein labeled and incubated in 96well plates precoated with 5µg/ml of the indicated protein. Non-adherent cells were
removed by gentle washing. Remaining adherent cells were lysed and fluorescence
quantified in a microplate reader was normalized to a standard curve of labeled cells. (A)
HAS3 transfectants adhere poorly to type IV collagen (Col IV) and fibronectin (FN),
relative to all other cell lines. * p<0.01 relative to GFP values. (B) HAS3 transfectants
were preincubated in the absence (gray bars) or presence (dark bars) of Streptomyces
hyaluronidase prior to adhesion assay on the indicated substrates (Col I, type I collagen;
LM, laminin). (C and D) Cells were preincubated with integrin blocking antibodies
(5mg/ml) prior to assaying adhesion to type IV collagen (C) or fibronectin (D). From left
to right, cells were treated with media alone (marble bars), anti-β1 (black bars), anti-α1
(white bars), anti-α2 (light gray), or anti-α5 (dark gray). * p<0.01 relative to media alone.
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Adhesion to ECM proteins and subsequent engagement of survival mechanisms is
mediated at the cell surface by heterodimeric integrin receptors47-49. Each integrin
consists of an α and a β subunit, both of which combine to form an extracellular ligandbinding domain, with well characterized specificity for various ECM proteins. A single
transmembrane sequence anchors these receptors at the cell surface and an intracellular
signaling domain modulates cellular responses to ligand binding. We used function
blocking antibodies to implicate specific integrins in the differential adhesion we
observed. Adhesion to all four substrates was abolished by treatment with anti-β1
antibodies (Figures 2.5C, 2.5D and data not shown). Inhibition of α1 and α2 integrins
accounted for ≈70% of control cell adhesion to type IV collagen (Figure 2.5C), consistent
with cell surface expression of these receptors in 22Rv1 cells and with the previously
reported ligand specificity of the α1β1 and α2β1 integrin heterodimers. Dependence of
adhesion on α2 integrin was no longer observed for the HAS3 transfectants. The limited
adhesion of these cells was mediated completely by α1β1 integrin. Similarly, despite
rather low expression of α5 integrin on the cell surface of any of the transfectants (not
shown), adhesion of control, Hyal1, and HAS3 cells to the known α5β1 ligand,
fibronectin, was almost completely inhibited with anti-α5 blocking antibodies (Figure
2.5D). Hyal1/HAS3 transfectant adhesion to fibronectin was only inhibited by ≈15% with
these antibodies, possibly suggesting integrin use or activation state is altered in these
cells. Collectively, results are consistent with compromised cell adhesion by HAS
overexpression as an underlying cause of reduced tumor cell growth in vitro and in vivo.
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2.4.4

Development and Characterization of Inducible 22Rv1 Cells
To investigate the relationship between excess HA production and cellular growth

phenotype, we established an inducible expression system. Three 22Rv1 clones were
selected for stable expression of the VP16 tetracycline (tet) transactivator protein that
confers tet-dependent transcription (Tet-ON #1,2,3). Of these, 22Rv1 Tet-ON#1
expressed the highest levels of the transactivator and was characterized for inducible gene
expression by transient transfection with constructs encoding GFP or HAS3 (Figure 2.6).
The four-panel series shows results of GFP transient transfection. Bright field images
illustrated comparable confluency of cultures in the absence and presence of the tet
analog doxycycline (dox, Figure 2.6, panels A and B). Minimal GFP fluorescence was
observed in the absence of dox induction (Figure 2.6C) and dramatic GFP fluorescence
was induced by addition of dox to the culture medium (Figure 2.6D).
Similar transfections were performed to evaluate specific induction of HAS3
expression and HA production. Parental 22Rv1 cells and inducible 22Rv1 Tet-ON cells
were transiently transfected with tet-responsive GFP or HAS3 constructs as indicated
(Figure 2.6E). Cells were incubated in the presence (+) or absence (-) of dox prior to
collecting conditioned media and cell lysates. In the inset panel, lysates from 22Rv1 TetON transfectants were analyzed by western blot probed with anti-Flag antibody. Robust
induction of HAS3 was observed with respect to control GFP and uninduced HAS3
transfectants. Some leakiness in expression was observed, as the HAS3 band was also
faintly visible in the uninduced lysates.
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Figure 2.6 Characterization of inducible 22Rv1 cells. 22Rv1 Tet-ON cells were
transiently transfected with constructs encoding GFP or HAS3 under the control of a Tet
sensitive promoter. Bright field images of inducible GFP transfectants in the absence (A)
or presence (B) of 2 g/ml dox were photographed at 200x magnification. Induction of
GFP expression was visualized by fluorescence microscopy in the absence (C) or
presence (D) of dox. (E) HAS3 protein induction was verified by western blots of whole
cell lysates probed with anti-Flag. Resultant HA production by transiently transfected
22Rv1 cells (left set of bars) in the absence (white bars) or presence (black bars) of dox
was compared to HA production by similar transfectants of the 22Rv1 Tet-ON cell line
(bars on right). * p<0.01 relative to GFP transfectants. ** p<0.01 relative to uninduced
HAS3.
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HA content of the media correlated well with expression levels of HAS3 protein.
As expected, the inducible construct did not confer HA synthesis to the parental 22Rv1
cells that lack the tet transactivator protein. Transfection of 22Rv1 Tet-ON with the
inducible GFP construct also did not stimulate HA production. A significant amount of
HA was produced by the uninduced HAS3 cells, consistent with HAS3 protein
expression, but dox incubation induced HA production by an additional 4-fold.

2.4.5

Induced HA Synthesis Impairs Cell Growth but can be Compensated with

Exogenous Hyaluronidase
We evaluated growth of the 22Rv1 inducible cells as described above for the
stable transfectants (Figure 2.7A). 22Rv1 Tet-ON cells were transiently transfected with
inducible constructs for GFP (squares) or HAS3 (circles). Cells were plated in the
absence (open symbols) or presence (filled symbols) of dox. Induction of the GFP control
did not impact growth. HAS3 transfection reduced growth somewhat even in the absence
of dox, since the uninduced cells still produced significant amounts of HA. However,
induction of HAS3 further impaired growth of the cells to a total of ≈ 50% overall.
Considering the transfection efficiency of the cells was also about 50%, these
measurements probably underestimated the full suppressive effect of HAS3
overexpression. Importantly, adhesion to fibronectin and type IV collagen was not altered
by HAS3 induction (data not shown), suggesting changes in integrin-mediated adhesion
are a stable adaptation to long term elevated HA synthesis.
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Figure 2.7 Growth kinetics of inducible transfectants in culture. (A) Equal numbers
of 22Rv1 Tet-ON cells transiently transfected with inducible GFP (squares) or HAS3
(circles) constructs were plated in quadruplicate in the absence (filled symbols) or
presence (open symbols) of 2 µg/ml dox. * p<0.01 for HAS3 uninduced transfectants
relative to uninduced GFP and for HAS3 induced relative to HAS3 uninduced. (B)
Growth of inducible HAS3 transfectants was similarly assayed in the absence (white
bars) or presence (gray and black bars) of dox. The effect of enzymatic HA removal by
exogenously added hyaluronidase was compared by assaying growth of the induced
transfectants in the absence (gray bars) or presence (black bars) of 0.1 U/ml of
Streptomyces hyaluronidase added at day 3. * p<0.01 relative to induced, untreated (gray
bars vs. black bars). (Inset) HA content of cell culture conditioned media from the assay
was quantified by competitive binding assay at the days indicated.
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Stable Hyal1/HAS3 cotransfectants exhibited normal growth, so we tested the
cells induced for HAS3 expression to determine whether exogenously added
hyaluronidase could restore growth kinetics. 22Rv1 Tet-ON cells transiently transfected
with the inducible HAS3 construct were plated in the absence (Figure 2.7B, white bars)
or presence (2.7B, gray and black bars) of dox. By day 2, growth of induced cells was
reduced by ≈30%. Black bars illustrate growth of HAS3-induced cells with daily addition
of Streptomyces hyaluronidase (0.2 mU/ml) to the culture medium starting at day 3.
Impaired cell growth, reduced by 45% as of day 7 in the untreated induced cells (gray
bars), was fully relieved by supplementation with hyaluronidase throughout the assay
(black bars). To correlate this observation with HA production by the cells, HA content
of the media was measured on the indicated days throughout the growth assay (Figure
2.7B, inset panel). HA content of the growth-impaired HAS3-induced cell media (gray
bars) was elevated ≈2-fold at day 2 and ≈10-fold at day 6 relative to the uninduced media
(white bars). HA content of media from hyaluronidase treated cells decreased (following
hyaluronidase addition at day 3, black bars) in inverse correlation to the increase in cell
growth.
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2.4.6

Temporal Control of HA Production Directly Influences Growth Kinetics of

Tumor Cells
The inducible system afforded us the advantage of being able to control the
temporal expression of HAS3 and correlate resultant HA production with growth curves.
22Rv1 Tet-ON cells transfected with the inducible HAS3 construct were plated in the
absence (Figure 2.8A, white bars) or presence (gray and black bars) of dox. Inhibited cell
growth in the dox induced groups was evident (≈43%) by day 4 (arrowhead). At this
time, all cell culture media were replaced: cells represented by white bars were again
given standard culture media and gray bar wells received dox-containing media. Black
bars represent cells from which dox-containing media were removed and replaced with
standard media at day 4. Removal of induction conditions restored growth rate of the
latter group by day 8. Levels of HA measured in the conditioned media from each group
of cells showed an expected drop due to media replacement at day 4, but whereas the
induced cells began replacing HA (Figure 2.8B, gray bars), induced cells from which dox
was removed (black bars) did not resynthesize HA. It should be noted that the magnitude
of HA induction was lower when cells were induced at day 4, relative to day 0, probably
resulting from expected plasmid copy number decrease following transient transfection.
It is also apparent that relatively low amounts of HA synthesis (e.g.; ≈3-fold induced in
the day 4 group) translated to a 31% decrease in cell count by day 6. These results are
consistent with a direct correlation between elevated HA production and growth
inhibition, and demonstrate that this inhibition is rapidly relieved by cessation of HA
synthesis.
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Finally, we plated 22Rv1 Tet-ON HAS3 transfectants in the absence (Figure
2.8C, white and black bars) or presence (gray bars) of dox. Growth impairment in the
induced group was again evident by day 4 (arrowhead), at which time culture media were
again replaced. In this experiment, cells represented by the black bars were given doxcontaining medium to induce HAS3 expression at day 4. Whereas these cells had
exhibited an identical growth rate to the uninduced controls up to day 4, cellular growth
was significantly slowed by day 6 (p<0.05 for day 6 and day 8). HA levels in the culture
media at each time point again reflected a direct relationship between HA production and
growth suppression (Figure 2.8D). Collectively, the results of this work indicate that
levels of HA produced by HAS3 overexpression in prostate tumor cells are antiangiogenic and anti-proliferative in subcutaneous tumors. Furthermore, removal of
accumulated HA, either by enzymatic degradation through hyaluronidase or reduction of
HAS3 expression, correlates directly to increases in tumor cell growth.
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Figure 2.8 Temporal effects of HAS3 induction on cell growth. 22Rv1 Tet-ON cells
transiently transfected with the inducible HAS3 construct were assayed for growth in the
continuous absence (white bars) or presence (gray bars) of dox (A and C). HA content of
conditioned media was determined at each corresponding time point (B and D). In panel
(A), dox-containing media were removed and replaced with standard culture media
(black bars). * p<0.01 for removed induction at day 4 (black bars) vs. continuously
induced (gray bars). Color schemes used in the corresponding plot of HA content are the
same (B). In panel (C), uninduced cells were given dox at day 4 (black bars). * p<0.01
for day 4 induced (black) vs. continuously uninduced (white bars). (D) HA content of day
4 induced cells is shown.
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2.5

DISCUSSION
Accumulation of HA and immunohistochemical detection of Hyal1 in human

prostate tumor specimens is predictive of cancer recurrence following therapeutic
intervention4,8. In prostate tumor cell lines, aggressive potential of the cells correlates
with 20-fold excess HAS3, but the relevance of this correlation has not been determined.
We stably overexpressed HAS3 in prostate tumor cells and found that the resultant excess
HA production by the cells suppressed tumorigenesis, in part by retarding intrinsic
growth. Excess synthesis of HA led to changes in integrin-mediated cell adhesion that
may translate to tumor cell anoikis in the collagen-rich subcutaneous environment, but
probably also inhibit tumor cell cycle progression. Coexpression of Hyal1 restored
adhesion and growth in culture, but Hyal1 activity was insufficient to clear the
accumulated HA in vivo. Thus, although Hyal1/HAS3 cotransfectant tumors were
vascularized comparably to control tumors, HA polymers persisting within the tumors
continued to suppress tumor cell proliferation. Use of an inducible expression system
allowed us to determine an inverse correlation between tumor cell HA synthesis and
growth kinetics that was independent of effects on cell adhesion, thereby implicating an
additional HA receptor-mediated pathway for inhibition of cell cycle progression.
Collectively, the data support a role for HA in initiating changes in cell surface receptor
engagement that may be amplified and exploited subsequently in tumor promotion upon
local HA dispersion. Therefore, HA processing by elevated Hyal1 expression in invasive
prostate cancer is likely required for progression.
The normal functions of HA are extremely diverse, despite its chemical simplicity
(reviewed in14,25). HA is a linear anionic polymer comprised of a single repeating
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disaccharide motif, critical for regulating cell division, cell motility and cellular
transformation during development13,50-56. HA polymers and HA oligosaccharides have
been implicated in distinct aspects of these processes. Responses to HA are mediated by
cell surface receptors that cluster when bound to the multivalent HA polymers, and
disperse when not bound, differentially triggering intracellular signals. For example, HA
polymers stabilize focal adhesion contacts by clustering specific cell surface receptors
that modulate cytoskeletal linker protein function18,57. Subsequently engaged signal
transduction pathways halt cell cycle progression and inhibit cell motility. Polymers
thereby preserve cell-free space in vivo by limiting proliferation and preventing
endothelial infiltration for angiogenesis. Disruption of the HA polymer/receptor
interaction by clearance of the polymers, or by competition of receptor binding with HA
oligosaccharides24,25,58-60, correspondingly may stimulate proliferation, motility, and
angiogenesis. Depending upon the size of the oligosaccharides, cells may also undergo
apoptosis, anoikis or autophagy. Thus, it is important for overall tissue homeostasis that
HA production and processing are tightly controlled.
Consequences of excess HA production have been previously investigated by
manipulation of HAS enzyme expression in several cell types. Mammary carcinoma61,
fibrosarcoma62, or melanoma cells63 that overexpress HAS1 or HAS2 are more
tumorigenic and/or metastatic in mice. Conversely, inhibition of HAS2 or HAS3
decreases HA production and reduces tumorigenic potential of the cells45,64. Some
controversy exists about potential differences in the HA polymers produced by different
HAS isozymes. However, there is considerable overlap of the ranges of polymer sizes
obtained, and no chemical or kinetic evidence for intrinsic differences in HA production

99
among the isozymes. This suggests differential effects of HA polymers are largely
dependent on quantity, which is dictated primarily by HAS expression levels.
The effect of HA on tumorigenesis was recently found by Itano, et al., to be
concentration dependent26. Stable transformed fibroblast lines selected for different levels
of HA production by HAS1 overexpression were proportionally more tumorigenic when
synthesizing moderate amounts of HA, but tumor growth was inhibited somewhat in cells
that produced excessive quantities. This result helps explain the anomaly in our findings
that HAS3 is anti-angiogenic and anti-proliferative in prostate tumorigenesis. HAS3 was
previously overexpressed in TSU cells, formerly thought to be of prostate origin but
reclassified as bladder-derived65, and found to enhance tumorigenesis and metastasis66.
However, levels of HA were not measured with respect to cell culture concentrations so it
is not possible to determine whether quantities fell into the tumorigenic range of the
curve determined by Itano, et al. Hyaluronidase expression was also not characterized in
these cells and may have played a role in relief from HA suppression of growth. Of note,
HA quantities produced by both HAS3 and Hyal1/HAS3 transfected cells in the current
study exceeded the levels shown to suppress tumor growth.
Achieving temporal control of HA production with the HAS3 inducible system
afforded an opportunity to directly link the effects of differential HA levels on tumor
growth in a constant cellular background. An additional observation was made possible
by the comparison of stable lines selected for long term constitutive overexpression of
HAS3 with those transiently induced to overexpress HAS3. Suppression of cell growth
was observed in both conditions but adhesion to ECM proteins was only inhibited when
HA overproduction was constitutive and stable. Disruption of cell-ECM interactions by
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altered integrin function has been associated extensively with cell death by anoikis48,67,68.
However, specific integrins (α1β1, α5β1 and αvβ3) have been shown to interact with the
adaptor protein Shc to stimulate an alternative pathway for cell cycle progression67,69. We
used integrin blocking antibodies to define the contribution of specific integrins to the
residual adhesion of HAS3 transfectants to type IV collagen and fibronectin. Despite the
dependence of control and Hyal1/HAS3 cotransfected cells on multiple integrins for
binding to both collagen and fibronectin, HAS3 transfectants were completely dependent
on α1β1 and α5β1, respectively. However, significantly reduced adhesion to these
substrates implies correspondingly diminished receptor function. Thus, this may translate
to a failure of HAS3 transfectants to stimulate cell cycling, as well as cell survival, in
response to ECM proteins in vitro and in vivo.
In contrast, the inducible HAS3 transfectants adhered comparably to all ECM
substrates relative to controls. Thus, they are unlikely to be experiencing changes in
integrin-mediated survival or cell cycle entry that would account for their decreased
growth kinetics. Rather, these cells showed growth suppression only with sustained HA
synthesis and accumulation in the conditioned media. Thus, it is likely that HA retention
at the surface of the tumor cells themselves is transducing the signal for growth
suppression. Previous reports of HA-induced cell cycle arrest have implicated the
transmembrane HA receptor CD4418,57,70,71 as the critical cell surface signaling contact.
CD44 promotes cell cycle progression in the absence of HA polymer ligation through
differential association with cytoskeletal linker proteins such as ezrin18,57. Presence of HA
polymers elevates a tumor suppressor protein, merlin, which binds the CD44 intracellular
signaling domain, precluding direct association of CD44 and ezrin. In fact, ezrin was
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recently investigated as a cancer progression marker and though the role in progression
was inconclusive, both ezrin and merlin were found to be expressed in prostate tumor
cells72. Thus, reduced cell growth by HAS3 overexpression may result from direct HA
suppression of cell cycling through CD44/merlin, in addition to cell cycle arrest by
altered integrin function.
During normal cellular HA turnover, high molecular mass HA polymers are
processed to relatively short polymers and/or oligosaccharides by hyaluronidasecatalyzed hydrolysis16. Initial extracellular processing of HA to short polymers was
recently demonstrated in cultured cells, dependent upon the expression of Hyal2. Cellular
uptake of HA was subsequently found to require Hyal1, and was augmented by CD44.
The authors proposed that extracellular Hyal1 bound HA and mediated its association
with Hyal2 and CD44 at the membrane, where Hyal2 initiated hydrolysis. Once inside
the cell, HA-Hyal1 complexes were ultimately localized to lysosomes, where the low pH
activated Hyal1 for complete cleavage of HA to tetrasaccharides. Apparent activity of
Hyal2 has also been shown to be enhanced by association in lipid rafts with CD44 and a
Na+/H+ antiporter that locally acidifies membrane microdomains34. Thus, although
Hyal1 has been shown to have optimal hyaluronidase activity at acidic pH, it is possible
through HA-mediated complex formation within these acidic membrane domains, both
Hyal1 and Hyal2 may be contributing to extracellular HA processing. Particularly in the
context of acidic regions within tumor micro- environments, excessive presence of either
Hyal1 or Hyal2 could be expected to yield excesses of extracellular HA degradation
products that would normally be confined within the cell. The outcome could range from
cell transformation to angiogenesis.
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In fact, Hyal1 and Hyal2 have both been implicated in cancer progression. Hyal2
is found elevated in conjunction with HAS2 and CD44 in invasive breast cancer73. Hyal1
is correlated with aggressive cancer progression because its expression in human prostate
tumor tissue samples predicts poor patient outcome8. Overexpression of Hyal1 in PC3M,
a metastatic prostate tumor cell line, modestly increased lymph node positivity in an
orthotopic model74. We have also determined that constitutive overexpression of Hyal1 in
22Rv1 cells, which are normally non-metastatic, induces metastasis to paraaortic nodes
upon orthotopic injection, though there was no effect on growth at the primary site28.
Hyal1 may be required to release tumor cells from cell cycle and motility suppression
imposed by HA-rich primary tumor tissues. HAS3 overexpression correlates with
metastatic phenotype in multiple lineage derived tumor cell lines such as prostate and
colon75. Hyal1 expression may rise in tumor tissues subsequently to HAS overexpression
as a selected compensatory mechanism for growth suppression. Our finding that
exogenous hyaluronidase can relieve growth suppression in vitro further implies that the
source of the hyaluronidase in vivo can be exogenous, perhaps secreted by tumorassociated stromal cells or macrophages.
Constitutive HAS3 expression suppressed subcutaneous tumor growth and
angiogenesis, which was not compensated by Hyal1 coexpression, despite the restored
growth of cotransfectants in vitro. One possible explanation for this observation is that
Hyal1 activity may be antagonized by endogenous hyaluronidase inhibitors76. This effect
was not observed in our previous studies of Hyal1/HAS2 cotransfectants, however,
suggesting rather that Hyal1 levels are insufficient to compensate for the increased HA
production by HAS3 (about 5-fold higher than HA production by HAS242).
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Hyaluronidases have been shown to be inhibited by excess HA polymer concentrations in
vitro77, so this may also be the case in vivo, particularly depending on local fluctuations
in tumor pH. Consistent with this notion, in our initial experiments with exogenous
hyaluronidase addition to HAS3-induced tumor cells, we found that daily augmentation
of hyaluronidase was essential to observe the effects of restored cell growth. In addition,
measurements of Hyal1 activity in our assays of culture conditioned media (Figure 2.1C)
showed submaximal specific activity until significantly diluted. Furthermore, significant
HA accumulation was detected in tumor sections, suggesting that although Hyal1
expression ameliorates growth suppression in culture, its ability to do so in vivo requires
HA diffusion to relieve inhibition. Diffusion of HA may be more constrained in a threedimensional tissue context.
Tumor size is a function of apparent tumor cell growth kinetics, whereas
vascularization of the tumor is a response to a tumor-provided signal or a tumor-induced
environmental cue. The data we have provided in vitro have highlighted two pathways by
which HAS3 overexpression could be expected to result in suppression of tumor cell
proliferation. Excessive HA could utilize similar signaling mechanisms to suppress the
recruitment and proliferation of endothelial cells required for angiogenesis of HAS3overexpressing tumors. Similar impairment of Hyal1/HAS3 transfectant tumor growth,
however, occurred despite unsuppressed angiogenesis. This could be partially explained
by ≈50% HA clearance of these tumors relative to the HAS3 tumors, but if restored cell
cycle entry was solely responsible for vascular development, tumor cell proliferation in
the HA deficient regions would also be expected. Thus, we propose that angiogenesis is
the result of endothelial cell recruitment by a tumor cell product generated within those
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regions. This recruitment signal could either be Hyal1-bound HA complexes, or could be
partially hydrolyzed HA polymers/oligosaccharides, response to which would be
mediated by endothelial CD44. Further experiments will be required to define aspects of
this model.
In summary, we have developed a useful system with which to fine tune levels of
HA production and uncouple the temporal effects of HA on growth control versus
tumorigenesis. The direct relation of HA production to suppression of tumor growth and
angiogenesis resolves the question of whether the product of HAS is intrinsically
tumorigenic. Our findings imply that concurrent HA production and adequate processing
activity are a requirement for maximal tumorigenic potential. The establishment of a
direct relationship between cell growth rate and HA production implies that sudden
immediate changes in HA production can control tumor growth. Since HA levels
influence tumorigenesis in a dose dependent fashion, the sudden complete removal of HA
production may impair growth of an established tumor in the same way high levels
suppressed growth. Thus, the inducible system will permit us to test the relationship
between HA and maintenance of established tumors in the same way we have
investigated its role in tumor formation. A further advantage of the system is the ability to
control HA levels within the same cellular background, thus avoiding some of the pitfalls
of clonal selection. It will be important to test this relationship in orthotopic
tumorigenesis and metastasis. We are currently developing stable inducible lines to
perform these studies.
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CHAPTER 3

SPONTANEOUS METASTASIS OF PROSTATE CANCER IS PROMOTED BY EXCESS
HYALURONAN SYNTHESIS AND PROCESSING

Note: The results in this chapter have been published. The authors are Alamelu G.
Bharadwaj, Joy L. Kovar, Eileen Loughman, Christian Elowsky, Gregory G. Oakley and
Melanie A. Simpson. The animal work described in this chapter were carried out by Joy
L. Kovar and Dr. Melanie A. Simpson.
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ABSTRACT
Accumulation of extracellular hyaluronan (HA) and its processing enzyme, the

hyaluronidase Hyal1, predicts invasive, metastatic progression of human prostate cancer.
To dissect the roles of hyaluronan synthases (HAS) and Hyal1 in tumorigenesis and
metastasis, we selected non-metastatic 22Rv1 prostate tumor cells that overexpress
HAS2, HAS3, or Hyal1 individually, and compared to cotransfectants expressing Hyal1
+ HAS2 or Hyal1 + HAS3. Cells expressing only HAS were less tumorigenic than vector
control transfectants upon orthotopic injection in mice. In contrast, cells coexpressing
Hyal1 + HAS2 or Hyal1 + HAS3 showed >6-fold and >2-fold increased tumorigenesis,
respectively. Fluorescence and histologic quantification revealed spontaneous lymph
node metastasis in all Hyal1 transfectant implanted mice, and node burden increased
another 2-fold when Hyal1 and HAS were coexpressed. Cells only expressing HAS were
not metastatic. Thus, excess HA synthesis and processing in concert accelerates
acquisition of a metastatic phenotype by prostate tumor cells. Intratumoral vascularity did
not correlate with tumor size or metastatic potential. Analysis of cell cycle progression
revealed shortened doubling time of Hyal1 expressing cells. Adhesion and motility on
extracellular matrix were diminished in HA overproducing cells. However, motility was
increased 2-fold by Hyal1 expression and 4-6 fold by Hyal1/HAS coexpression, in close
agreement with observed metastatic potential. This is the first comprehensive
examination of these enzymes in the relevant microenvironment for prostate cancer.
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3.2

INTRODUCTION
Prostate tumors detected early are often managed effectively by surgical resection

and/or hormone ablation therapy. However, a significant percentage of tumors resume
growth in the absence of androgens1. The transformation from androgen dependent to
androgen independent prostate cancer is incompletely understood, and such tumors are
typically highly aggressive. Progression of human prostate cancer to invasive and/or
metastatic growth is accompanied by significant deposition and accumulation of
hyaluronan (HA) within the tumors. HA is a large secreted glycosaminoglycan polymer
that normally functions in motility and cell transformation during development and
wound healing2-5. Matrices rich in HA tend to be comparatively deficient in covalently
cross-linked fibrous protein networks6, more gel-like and less organized, thus altering the
normal architecture of the tissue matrix by increasing its permeability. This undermining
of tissue structural integrity may be permissive to pathological cell proliferation and
movement, particularly in cancer4. Furthermore, its role as an adhesion and migration
substrate for cells in development may translate to enhanced metastatic potential of cells
bearing surface associated HA.
Many previous reports have documented the involvement of HA and its receptors
in prostate cancer progression7-13. In human prostate cancer patients, high levels of HA
correlated with locally invasive tumor growth and PSA recurrence, both independent
indicators of negative prognosis7. Quantification of the HA processing hyaluronidase,
Hyal1, was demonstrated to be predictive of continued disease progression following
hormone ablation therapy11, which is normally effective in early stage prostate cancers.
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Our previous research has differentially implicated HA synthase isozymes HAS2
and HAS3, both of which produce HA polymers, in conjunction with Hyal1, which
processes HA polymers to oligomers, in aspects of aggressive tumor progression14-19. In
particular, excessive cellular HA retention and autocrine processing was predicted to
promote metastasis. Among cultured human prostate tumor cell lines, elevated HA
production was found specifically in aggressive, metastatic cells, in which HAS2 and
HAS3 isozymes were upregulated ≈3-fold and ≈30-fold, respectively17. Suppression of
HAS2 and/or HAS3 expression by stable antisense RNA reduced the synthesis and cell
surface retention of HA18, and inhibited primary subcutaneous19 or intraprostatic
growth20. Reduced primary tumor growth was associated with comparable apoptotic and
proliferative fractions in culture and in tumors, but virtually no vascularization of tumors.
These results implicate HA, and specifically HAS2 and HAS3, in tumor angiogenesis, as
well as intrinsic growth rate modulation. Interestingly, exogenous HA addition to knockdown cells upon injection restored subcutaneous tumor growth and angiogenesis,
implying the existence of a tumor or stromal factor (i.e.; a hyaluronidase) that could
modulate effects of HA in trans, with the same malignant outcome. We hypothesized that
concerted action of these enzymes at elevated levels in prostate tumors would facilitate
aggressive primary tumor growth by potentiating tumor cell proliferation and
vascularization of tumors.
To segregate the effects of HA synthesis by the HAS enzymes from HA turnover
by Hyal1, we previously selected 22Rv1 prostate adenocarcinoma cells to stably
overexpress Hyal1, HAS2, or HAS3, and to coexpress Hyal1+HAS2 or Hyal1+HAS3.
Growth kinetics in culture and in subcutaneous murine tumors were compared14-16. HAS2
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expressed alone or coexpressed with Hyal1 in 22Rv1 tumor cells increased subcutaneous
growth and vascularization of tumors. In contrast, overexpression of HAS3, which
conferred 20-fold higher HA production than GFP controls and 5-fold more than HAS2
transfection, diminished subcutaneous tumor growth and vascularization. Since the
subcutaneous microenvironment is already a site of abundant HA turnover, we reasoned
that the physiologically relevant microenvironment of the prostate, normally a site of low
HA production and turnover, might be impacted differently by tumor cells with these
properties, in a manner more representative of the human disease. Therefore, the goal of
this study was to define the respective roles of HA synthases and hyaluronidases for the
first time in orthotopic growth and metastasis of prostate tumor cells, and identify the
underlying cellular processes affected.

3.3

MATERIALS AND METHODS

3.3.1

Cell Culture and Reagents
22Rv1 human prostate adenocarcinoma cells from ATCC were cultured in RPMI-

1640/10% FBS as recommended. Stable transfectants were maintained in standard media
supplemented with 1.5 mg/ml G418. Biotinylated HA binding protein (HABP) was from
Seikagaku. Anti-mouse CD31-phycoerythrin conjugate was from BD Biosciences
Pharmingen. Collagen type IV was from Fisher Biosciences. Standard mouse chow and
purified maintenance diet (AIN-93M) were obtained from Harlan Teklad (Madison, WI).
IRDye® 800CW EGF was supplied by LI-COR Biosciences (Lincoln, NE). The
Odyssey™ Infrared Imaging System was also provided by LI-COR Biosciences.
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3.3.2

Orthotopic Injection
Male NOD/SCID mice (Jackson Labs, Bar Harbor, ME) were cared for and

maintained under the supervision and guidelines of the University of Nebraska-Lincoln
Institutional Animal Care and Use Committee. Six-week-old mice were anesthetized with
2% isoflurane and injected in the left lobe of the dorsal prostate with 1x105 22Rv1
transfectant cells (7 mice per group) suspended in serum free medium. Tumor growth
was tracked by optical imaging at 2, 4, and 6 weeks, each time three days following
intravenous injection of 1 nmol IRDye 800CW EGF targeting agent. Control animals
injected only once at the endpoint confirmed that no differences in tumor size occurred
within animal groups as a result of longitudinal exposure to the agent. In addition, tumor
weights and lymph node H/E staining were repeated with identical results in a second
experiment using eight animals per group, in which imaging was not used.

3.3.3 Near Infrared Imaging of Tumors and Lymph Nodes
NIR fluorescence imaging in live animals was performed with a prototype small
animal imager as previously described15. Images were acquired and analyzed with
Wasabi software from Hamamatsu Photonics (Hamamatsu City, Japan) or Adobe
Photoshop (Adobe Systems Inc., San Jose, CA). For longitudinal tracking, shaved
anesthetized mice were imaged in a sealed, sterilized portable compartment, circulated
with HEPA-filtered air.
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3.3.4

Statistical Analysis of Animal Fluorescence Data
Images analyzed in a longitudinal series for each mouse were normalized using

the same look up table with a common minimum and maximum value. Signal-to-noise
ratio (SNR) was calculated using the following formula:
SNR =

Maximum tumor intensity ‐ Mean background intensity
Standard deviation of mean background

Regions of interest (ROI) with identical areas were quantified for total pixel and mean
pixel values. The standard deviation of mean backgrounds was calculated using 3-5
ROIs. Statistical variance among tumor wet weights and lymph node metastatic burden
was calculated by one-way ANOVA comparing each group mean to the GFP control
group. Group means were evaluated for significance at probability values of 0.05 and
0.01.

3.3.5

Immunohistochemistry and Immunofluorescence
HA content and vascularization of tumors were detected as described

previously16,19. Briefly, tumors were divided in halves. One half was formalin fixed and
embedded in paraffin. The other half was snap frozen in OCT compound. For HA
detection, paraffin-embedded tumors were sectioned, dewaxed, incubated with 3 μg/ml
biotinylated HABP in PBS/1% BSA overnight at 4˚C, and developed using the
Vectastain ABC kit (Vector Laboratories, Irvine, CA). Sections were counterstained with
Meyer’s hematoxylin. White light images were collected at 200x magnification.
Vascularization of the tumors was assessed in acetone fixed frozen sections (8 μm
thickness) by antibody staining for CD31 as described previously14,16,19,21.
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3.3.6

Angiogenesis Quantification
CD31-phycoerythrin conjugated antibody staining of frozen sections was

visualized by fluorescence microscopy. Ten random sections from each of three tumors
per cell line were digitally photographed with 5 s exposure time, saved as TIF files, and
processed. Average pixel density for each transfectant tumor section was normalized to
the average pixel density for untransfected tumor sections. One-way ANOVA was used
to determine if variance in total vascular pixel density among the 30 images for each
transfectant tumor group was significantly different from 30 images of the GFP control
transfectant tumors. Significance was evaluated at probabilities of 0.05 and 0.01.

3.3.7

Cell Cycle Analysis
Transfectant tumor cells cultured in standard medium were trypsinized, washed,

fixed overnight at -20˚C, and stained overnight at 4˚C with propidium iodide containing
RNase. Cells were analyzed by flow cytometry using a FACSArray Bioanalyzer (BD
Biosciences) with ModFit Software. Percentages of each transfectant cell type in
respective phases of the cycle were plotted (asynchronous). To synchronize cells, which
were not susceptible to serum synchronization, we treated for 24 h with 0.2 mM
nocodazole, a mitotic inhibitor. Treated cells were segregated into two pools, one of
which was continually exposed to nocodazole (arrested) and one from which nocodazole
was removed for 24 h prior to assay (arrested and released). Cells were analyzed
similarly to the asynchronous population. Statistical significance at each time point was
assessed by one-way ANOVA relative to GFP control values.
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3.3.8 Extracellular Matrix Adhesion
Microplates were precoated with type IV collagen in serially diluted doses for 1 h
at 37˚C and blocked with 3% BSA. Subconfluent cells were released with 1mM EDTA,
washed, resuspended in adhesion medium (serum-free RPMI 1640 containing 20 mM
HEPES, pH 7.2, and 1% BSA), and labeled with calcein-AM (25 μg/106 cells, 20 min at
37˚C). Labeled cells (104 cells/well) were incubated in quadruplicate wells of the
precoated plates for 2 h at 37˚C. Non-adherent cells were removed with three gentle
washes in adhesion medium. Remaining adherent cells were lysed; fluorescence was
quantified and the percentage of adherent cells relative to the input number was
calculated from a standard curve of each labeled cell culture. Significance was
determined by one-way ANOVA.

3.3.9

Motility
Motility of the transfectants was assayed using a 48-well modified Boyden

chamber (Neuroprobe, Inc., MD). Briefly, single cell suspensions (20,000 cells/well) in
serum free RPMI were placed in quadruplicate into the upper wells of the chamber with
type IV collagen (10 μg/ml) in the lower well. Membranes used to separate the wells
were 8μM pore size. Following 20 h incubation at 37˚C in a humidified chamber,
membranes were fixed and stained with Diff-Quik (Fisher Biosciences), and placed with
migrated side down on a glass microscope slide. Non-migrated cells were wiped away
with a cotton swab. Remaining migrated cells were counted at 150x magnification in five
random fields per well and plotted as mean ± SEM of average migrated cells per well.
Significance was determined by one-way ANOVA.
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3.4

RESULTS

3.4.1

Orthotopic Prostate Tumorigenesis is Enhanced by Coexpression of HA

Synthesizing and HA Turnover Enzymes.
To examine the role of HA metabolic enzymes in prostate tumorigenesis and
metastasis, we performed orthotopic injections in male NOD/SCID mice. From the
orthotopic site, we previously determined that 22Rv1 cells were non-metastatic but could
be induced to metastasize to the para-aortic lymph nodes within a six-week time course
upon overexpression of Hyal115. Growth of tumors was monitored over six weeks by near
infrared optical imaging using fluorescent dye conjugated to EGF. At two-week intervals,
images were collected and analyzed for total lower abdominal fluorescence at signal to
noise ratios of >3 standard deviations above background (Fig 3.1A). Differential growth
rates among the tumors were evident by week 2, with several consistent trends emerging
by week 4. At six weeks, prostates were harvested and weighed (Fig 3.1B). As we
observed previously, Hyal1 overexpression alone did not alter endpoint tumor size. Either
HAS2 or HAS3 expression suppressed intraprostatic 22Rv1 growth, with only ≈25%
(HAS2) and ≈58% (HAS3) of injected animals bearing tumors. Of the resulting tumors,
the overexpression of either HAS2 or HAS3 also reduced tumor size, though statistical
significance for HAS3 was not established (p=0.06). In contrast, concurrent expression of
HAS2 and Hyal1 or HAS3 and Hyal1 increased tumorigenesis ≈6-fold and ≈2-fold,
respectively.
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Figure 3.1 Orthotopic prostate tumorigenesis is enhanced by coexpression of HA
synthesizing and HA turnover enzymes. Single cell suspensions of transfected cell
lines as indicated were injected in 10 μl of serum-free RPMI to the dorsal prostate of
male NOD/SCID mice (7 per group, repeated in triplicate). (A) Tumor growth was
monitored longitudinally at two-week intervals by NIR optical imaging. Mice were
imaged 72 h after IV injection of IRDye 800CW EGF (1 nmol). Images were analyzed
for total tumor fluorescence detected at signal to noise ratios of >5 standard deviations
above background. (B) At six weeks post surgery, following the final image capture,
animals were sacrificed and tumors were harvested and weighed. Plotted is the mean
tumor wet weight ± SEM for all mice; * p<0.01.
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Suppressed growth of HAS-overexpressing cells is consistent with previously
characterized intrinsic growth rates of the respective cell lines in culture14,16. However,
the increased tumorigenic potential of Hyal1+HAS coexpressing cells in the otherwise
HA deficient prostatic environment exceeds the growth potential predicted by the
intrinsic kinetics in culture, suggesting additional parameters are important for prostate
colonization of the transfectants.
HA content of prostate tumors was evaluated by probing paraffin-embedded
sections with a specific HA binding protein (Figure 3.2). As expected, neither control
GFP nor Hyal1 tumor sections stained appreciably for HA. However, the HAS2 and
HAS3 tumors exhibited abundant HA accumulation at the cell surface and pooled within
regions of the tumor matrix. Importantly, coexpression of either HAS isozyme with
Hyal1 markedly reduced HA accumulation within the tumors. These observations are
consistent with growth suppression by HA in high concentrations produced by HAS, and
with relief from growth suppression upon Hyal1 mediated HA turnover.
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Figure 3.2 HA content of orthotopic tumor sections. Formalin-fixed paraffinembedded tumors were sectioned and stained with biotinylated HABP, followed by
detection with streptavidin-conjugated HRP and diaminobenzidine precipitation to
visualize HA content. Sections were counterstained with hematoxylin and representative
fields were digitally photographed at 200x magnification.
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3.4.2

Enhanced Tumorigenesis in the Prostate does not Correlate with

Intratumoral Blood Vessel Density
One potential explanation for increased tumor growth could be that Hyal1catalyzed degradation of HA may occur in the extracellular space22, giving rise to low
molecular weight HA oligosaccharides with angiogenic potential23, and thereby
promoting vascularization of the tumors. Therefore, we quantified the vascular density of
the tumor sections by probing with anti-CD31 (Figure 3.3 graph). In contrast to what we
expected, vascularization of prostate tumors arising from each of the cell lines was
modestly increased by HAS-mediated HA production but was unaltered by concurrent
HA processing. Interestingly, scrutiny of the raw images for each tumor analyzed (upper
panels of Figure 3.3) revealed a notable difference in the morphology of the intratumoral
vessels. Tumors arising from HAS overexpressing cells contained vasculature of more
robust appearance as judged by the intensity of fluorescence staining. They were also
more sparsely distributed within the tumor. Vessels occurring within GFP control tumors
and all Hyal1-expressing transfectant lines (Fig 3.3, right column panels) were
significantly finer in appearance and were more numerous per unit area than in the HA
rich tumors.
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Figure 3.3 Enhanced tumorigenesis in the prostate does not correlate with
intratumoral blood vessel density. Orthotopic tumors were embedded in OCT
compound and cryosectioned. Sections were stained with anti-CD31-PE conjugate and 10
randomly selected sections per tumor were digitally photographed under a fluorescence
microscope at 400x magnification with 5s exposure time. Representative images from
each tumor type as indicated are shown. Images were processed as indicated in Materials
and Methods to obtain total vessel area per section as pixel density. Mean pixel density
per section ± SEM is plotted for 10 sections of three different tumors per group;
* p<0.01, ** p<0.05.
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3.4.3 Spontaneous Lymph Node Metastasis is Initiated by Hyal1 and Potentiated
by HAS/Hyal1 Coexpression
Following tumor removal from the sacrificed mice, para-aortic lymph node
metastases were visualized by near infrared optical imaging (Figure 3.4). Representative
images of lymph nodes (LN) in situ were captured (Fig 3.4A) prior to excision of the
nodes. Ex vivo images were then collected (Fig 3.4B, 3.4D) and used to quantify node
fluorescence as a measure of metastatic burden in mice injected with each cell line.
Results were confirmed by histological staining of sectioned nodes from each animal in
the study (Fig 3.4C, 3.4E). Fluorescence intensity of the nodes was quantified and
normalized to that of the nodes from the GFP control group (Fig 3.4F). As we previously
found, overexpression of Hyal1 alone induced metastasis of non-metastatic 22Rv1 cells.
However, coexpression of either HAS isozyme with Hyal1 significantly increased size
and total fluorescence of lymph nodes by a further 2.3-fold (HAS2, p<0.01) or 1.7-fold
(HAS3, p<0.01). Therefore, the combined expression of Hyal1 and HAS provides a
synergistic stimulus for prostate tumor growth and metastasis.
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Figure 3.4 Spontaneous lymph node metastasis is initiated by Hyal1 and potentiated
by HAS/Hyal1 coexpression. Three days prior to study termination, mice were injected
IV with IRDye 800CW EGF (1 nmol). After final image capture, animals were sacrificed
and dissected to expose the para-aortic lymph nodes. (A) Images of lymph nodes in situ
from representative animals are shown for comparison at the same look-up table. Excised
lymph nodes from all animals in the study were imaged intact for fluorescence
quantification (B, D) and sectioned for histology (C, E). Nodes shown are from animals
injected with HAS2 (B, C) and Hyal1/HAS2 (D, E) transfectants. (F) Fluorescence
intensity (800 channel signal with SNR>3) of all excised nodes was normalized to
fluorescence of nodes from mice injected with control GFP transfectants. Mean ± SEM is
plotted; * p<0.01.
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3.4.4

Cell
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To determine mechanisms underlying the observed changes in vivo, we
investigated aggressive tumor correlate behaviors in vitro. We previously found that
HAS3 stable overexpression induced changes in cell surface integrin levels that resulted
in compromised adhesion of the cells to extracellular matrix proteins14. This is one
mechanism by which HAS expression may suppress cell growth in the absence of
sufficient hyaluronidase activity. Since impaired adhesion has the potential to impact
apoptosis, cell cycle progression and cell motility, we examined these characteristics of
the transfectants. Asynchronous populations of the transfectant cell lines were analyzed
by propidium iodide staining and flow cytometry. Percentages of cells in each phase of
the cell cycle, as well as the fraction of cells undergoing apoptosis, were quantified and
compared for each cell line. Results were plotted for a representative assay (Figure 3.5A).
The most striking points observed in these data were that cells overexpressing Hyal1
alone exhibited an increase from ≈18% to ≈30% in S phase (DNA synthesis), while the
G0/G1 (resting) phase fraction is similarly reduced. The intrinsic rate of Hyal1
transfectant proliferation is ≈50% faster than GFP control transfected cells, which is
consistent with a higher level of DNA synthesis and shorter overall doubling time.
Concurrent expression of Hyal1 with HAS3 also significantly increased the fraction of Sphase cells, consistent with restoration of their proliferative rates in culture and
acceleration of tumor growth kinetics in vivo. Surprisingly, Hyal1/HAS2 coexpressing
cells were not significantly different from controls. No appreciable differences in the
apoptotic fraction were observed among the cell lines.
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Figure 3.5 Cell cycle analysis reveals accelerated cell cycling of Hyal1overexpressing cells. Transfectant cell lines were fixed, permeabilized, propidium iodide
stained and analyzed by flow cytometry. Respective mean percentages of cells in each
phase of the cycle are plotted ± SEM for a total of three experiments in asynchronous
cultures (A). Cells were synchronized in the G2/M phase by nocodazole treatment, then
released by replacement with standard medium for the indicated times and similarly
analyzed by flow cytometry. Mean ± SEM of triplicate assays is plotted for each phase of
the cell cycle at each time point as indicated at the top of each column; * p<0.01. Plots
compare HAS2 (dark blue triangles), Hyal1 (black squares), and Hyal1/HAS2 (light blue
circles) cells (B) or HAS3 (red triangles), Hyal1 (black squares), and Hyal1/HAS3
(orange circles) cells (C).
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To investigate cell cycle alterations more carefully, we performed a time course
analysis of cell cycle re-entry following synchronization of the cells with the mitotic
arrest agent, nocodazole. Comparison of Hyal1 transfectants to GFP controls (Fig 3.5B,
3.5C) showed a significantly shorter time in G0/G1 resting phase, ≈6-7 hours versus 1214 hours, with consequent accelerated advance to S-phase. HAS2 (Fig 3.5B) transfectants
did not exhibit significantly different characteristics. It was evident that the Hyal1/HAS2
coexpressing cells failed to synchronize completely so the effect of coexpression on
specific phases of the cell cycle may be masked. HAS3 transfectants (Fig 3.5C) advanced
to S-phase more slowly than controls, ≈16-18 hours. Hyal1/HAS3 cotransfectants, though
entering S-phase at a similar rate to controls, exhibited an S-phase peak of comparable
magnitude to the Hyal1 cells. Thus, excess HA production has the potential to extend
time in the resting phase, while Hyal1 expression appears to reduce this time and
accelerate overall cell cycling.
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3.4.5

Cell Adhesion and Migration to Collagen are Impaired by HAS Expression

but Migration is Increased Synergistically with Hyal1 and HAS Coexpression
Finally, we examined cell adhesion and motility in response to the extracellular
matrix protein collagen IV, a normal component of the prostate basement membrane. To
assay adhesion, tumor cell suspensions were applied to collagen-coated microwell plates
(Fig 3.6A). HAS2 and HAS3 overexpressing cells, which bear abundant pericellular HA
relative to untransfected, Hyal1 transfected, or Hyal1/HAS cotransfected cells, were
≈50% less adherent to this substrate. In similar assays, the HAS transfectants were up to
80% less adherent on fibronectin or laminin coated plates (not shown). Reduced adhesion
is one likely explanation for the slower growth rate of these cells in vitro, but is not
necessarily coupled to intrinsic cell motility. To test this, we assayed migration of the
cells in a modified Boyden chamber (Fig 3.6B). Migration of the HAS transfectants was
modestly but significantly reduced relative to the GFP controls. Strikingly, although
Hyal1 individual and Hyal1/HAS cotransfected cells adhered comparably to GFP control
transfectants, cell migration of Hyal1 transfectants was significantly increased, and
further enhanced by Hyal1/HAS coexpression. Results of the cell migration assay directly
reflected the pattern of metastatic potential exhibited. Collectively, results of our
characterizations in vivo and in vitro, summarized in Table 1, implicate Hyal1 expression
in enhanced tumor cell intrinsic motility, as well as proliferation, and demonstrate that
the combined production of HA with the Hyal1 processing enzyme maximizes this
potential.
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Figure 3.6 Cell adhesion and migration to collagen are impaired by HAS expression
but migration is increased synergistically with Hyal1 and HAS coexpression. (A)
Cell adhesion to type IV collagen (5 μg/ml) was quantified in a precoated 96-well plate,
to which calcein-labeled tumor cell suspensions were added. Non-adherent cells were
removed by gentle washing after a 2 h incubation at 37˚C. Remaining adherent cells were
lysed and fluorescence of each well was normalized to a standard curve for each cell line.
Results plotted are the mean ± SEM of quadruplicate wells from a total of three
experiments; * p<0.01. (B) Cell migration was assayed in a modified Boyden chamber.
Stably transfected 22Rv1 cells as indicated were trypsin released and resuspended in
serum free RPMI. The lower wells of the chamber contained type IV collagen (10 μg/ml)
in serum free RPMI. Cells (20,000/well) were placed in quadruplicate wells of the upper
chamber, separated from the lower wells by a polycarbonate membrane with 8μM pore
size. After 20 h incubation at 37˚C, membranes were fixed and stained. Migrated cells
were counted in five random fields per well at 150x magnification. Average number of
cells per field is plotted ± SEM for each cell line; * p<0.01, **p<0.05.
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Table 3.1 Summary of transfectant prostate tumor cell characteristics.

GFP

Hyal1

HAS2

Hy1/H2

HAS3

Hy1/H3

Tumorigenesis

1

1.00

0.43*

6.24*

0.80*

2.03*

Metastasis

1

2.67*

1.32

6.00*

1.55

4.33*

Blood vessel density

1

1.11

1.84*

0.81

1.41

1.07

Apoptosis

No significant differences, <5% total cells

Proliferation

1

1.62*

Cell cycle
Asynchronous (S-phase)
Time to S-phase re-entry

12-14h

+12%
6-8 h

12 h

Adhesion

1

0.99

Migration

1

1.95*

* p<0.05 relative to GFP control
NA: not fully arrested

0.10*

1.14

0.54*

1.00

NA

16-18h

+7%
14-16 h

0.49*

0.85

0.51*

1.15

0.78*

5.00*

0.60*

2.57*
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3.5

DISCUSSION
Unfavorable prognosis for invasive prostate cancer is strongly correlated with the

combined presence of HA and Hyal1 in human resected prostate tumor tissue.
Independently, overexpression of either Hyal1 or HAS has been previously implicated in
promotion of subcutaneous tumorigenesis in mice16,24-26. However, the respective
importance of HA synthesis and processing enzymes in prostatic tumor growth kinetics
and metastatic potential has not been evaluated. In this study, we found that HAS
expression modestly suppressed prostate tumor cell growth at the orthotopic site, while
the combined production of HA with excess Hyal1 processing activity served to
accelerate primary tumor growth kinetics (Table 1). The expression of Hyal1 alone was
sufficient to initiate spontaneous lymph node metastasis while having no effect on
primary tumor size, but the simultaneous overproduction of HA further accelerated tumor
cell dissemination. We demonstrated these differential effects were independent of tumor
angiogenesis. Rather, they were attributable to altered cell cycle progression in the
presence of Hyal1 alone, and to increased motility stimulated by Hyal1 but significantly
enhanced by coexpression of HAS with Hyal1. This is the first study to dissect the
respective roles of the HA synthesis and processing enzymes in an orthotopic prostate
cancer progression model and to correlate with underlying cellular mechanisms.
Tumor cell responses to HA synthesis have been reported by a number of groups.
Several studies have found HAS overexpression promotes tumorigenesis24 or anchorage
independent growth27, while others found metastatic frequency increased without
impacting tumorigenesis28,29. Interestingly, many studies have also shown that large HA
quantities of high molecular mass (i.e.; >100 kDa) are antiproliferative and
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antiangiogenic30,31, capable of suppressing growth of both tumor cells16,32 and vascular
endothelial cells31. These responses are dependent upon both size and concentration of
HA. In fact, dose dependence of HA production was shown by selection of tumor cells
for different levels of HAS1 overexpression, which promoted subcutaneous
tumorigenesis at low levels while suppressing it at high levels33. However, it is clear that
the turnover of HA is critical for the observed phenotypic outcome of excess HA
synthesis. HAS was tumorigenic in gliomas only if cells expressed hyaluronidase32. In
breast cancer cell lines, expression of HAS2 and the hyaluronidase isozyme Hyal2 were
associated with invasive phenotype34. In our previous work, antisense HAS suppression
inhibited subcutaneous growth of tumor cells that could be restored by HA
supplementation19. In addition, concurrent overexpression of Hyal1 and HAS2 increased
tumor size several fold relative to either Hyal1 or HAS alone16. Collectively, these results
are consistent with our observations in the work presented here. Importantly, we
demonstrate that the excess production of HA is growth suppressive to the cells
synthesizing it, whereas the simultaneous elevation of turnover by Hyal1 provides a
growth promoting signal.
HA turnover by Hyal1 may provide an oligomeric HA signal in the extracellular
space35 that would compete with polymers for receptor binding at the cell surface.
Alternatively or in addition, Hyal1 may function in concert with Hyal2 to enhance tumor
cell reuptake of HA polymers36, with the majority of degradation taking place
intracellularly. We have quantified expression of other hyaluronidase isozymes, including
Hyal2, and found that although Hyal2 and Hyal3 messages are present, they do not show
differential expression among human prostate tumor cell lines and their expression did
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not change with any of our gene manipulations (Simpson, MA, unpublished), nor are
there any reports of their clinical involvement in prostate cancer. Presumably, these
enzymes are participating to an equal extent in the phenomena we have examined here.
Altered receptor engagement subsequent to cellular stimulation by HA polymers
versus HA oligosaccharides influences signaling pathways for cellular transformation and
apoptosis (reviewed in5). For example, targeted disruption of the HAS2 gene in mice
supports the implication of HA as an essential signal for epithelial to mesenchymal
transition that precedes cardiac septal formation37. This function of HA as a
transformation signal has been demonstrated in cancer progression as well, in which case
neoplastic transformations may be promoted by HA-mediated activation of receptor
tyrosine kinases such as ErbB238-40. Constitutive engagement of HA receptors by small
amounts of newly synthesized HA polymers was shown to stimulate cell cycling through
assembly of protein complexes including PI3-kinase, cdc37, and the cytoskeletal adaptor
ezrin40,41. In addition, HA responses are context dependent with respect to twodimensional versus three-dimensional culture conditions4. Anchorage independent
growth of prostate tumor cells requires HA polymer ligation of cell surface receptors to
stabilize cytoskeletal architecture by intracellular association with ankyrin, ezrin,
cytoskeletal proteins and other adaptors41,42. These interactions have been successfully
disrupted and shown to induce tumor apoptosis in vitro and in vivo by administration of
HA oligosaccharides41,43.
A component of HA signaling in transformation may be its influence on cell cycle
progression through physical processes. Pericellular HA matrices enlarge during mitotic
cell rounding and this cell-associated HA deposition facilitates de-adhesion during the
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G2/M phase of the cell cycle44. Intracellular HA was detectable and appeared to interact
with the mitotic spindle throughout cell division. The authors postulated that its extrusion
to the cytoplasm could be needed to exert steric or osmotic effects on trafficking of
intracellular components. Using metastatic Dunning rat prostate tumor cells, Koike et al45
observed that HA production may be induced in tumor cells by increasing mechanical
stress as the tumor enlarges, contributing to survival and anchorage independent
spheroidal growth of the tumor cells. We previously found that exogenously added
Streptomyces hyaluronidase could relieve the growth inhibition imposed by
overproduction of HA14. Consistent with our observations in the current study, Hyal1
isolated from plasma was previously shown to promote cell cycling, evidenced by
increased cells in the DNA synthesis (S) phase with reduced numbers in the resting
(G0/G1) phase46; also, G2/M arrest is the outcome of Hyal1 knockdown26. We have
further shown here that overproduction of HA (but not exogenous HA addition) lengthens
the duration of G0/G1 and delays S-phase entry. Collectively, these results are consistent
with a model in which HA is required both within the tumor cell to physically facilitate
accelerated progression through mitosis, and at the pericellular surface to permit cell
morphology changes essential to division. In this model, excess HA unbalanced by the
turnover activity of Hyal1 would inhibit processes such as chromosomal condensation
and/or DNA synthesis, possibly by steric or electrostatic interference, thus slowing entry
into G0/G1. The presence of Hyal1 may relieve HA inhibition through enhanced
clearance if sufficiently expressed to balance synthesis.
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An additional explanation for altered tumorigenesis and metastasis in conditions
of HA dysregulation is that HA antagonizes cell adhesion and motility. Excess HA
accumulation at the cell surface impairs integrin-mediated adhesion, so migration is also
affected, since cells must adhere and de-adhere to orchestrate nonrandom movements. In
part because of its anti-adhesive function but also as a result of receptor engagement, HA
has a prominent role in promoting cell migration. Pericardial explants from HA deficient
mice, which did not undergo endothelial cell migration needed for cardiac
morphogenesis, were shown to have restored motility in the presence of exogenous HA
or dominant negative ras37. Thus, HA can serve as a ras-dependent signal for cell
migration. A similar role for HA in genitourinary development was shown by monitoring
prostate ductal branching in embryonic explants47. In renal proximal tubular epithelial
cells, HA directly stimulates migration through MAP kinase activation48 and also
suppresses the anti-migratory TGFβ1 signal normally produced by the cells49.
Pericellular HA synthesis in response to prostate fibroblast conditioned media has been
observed to correlate with increased migration of prostate tumor cells50, where HA was
most densely deposited at the trailing edge of the polarized motile cells, consistent with
its potential role in de-adhesion. However, the overexpression of HAS isozymes has also
been shown to reduce motility51, as we have seen in the current report. In neither of these
prior cases was hyaluronidase activity investigated, however, so it is probable that HA
turnover differed among the cells tested, and that such differences contribute to the net
effect of HA production on cell motility. This notion is supported by our findings of
dramatically increased motility in the Hyal1/HAS transfectants: cells continually
synthesize the anti-adhesive surface HA, but since they rapidly turn it over, streaming
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and reattachment during movement are not hindered.
In summary, our finding that cell adhesion and motility are respectively restored
and enhanced by concurrent elevation of HA synthesis and HA turnover enzymes
supports the implication of HA in suppressed adhesion, growth and migration of tumor
cells. Thus, the observation of HA accumulation within tumor tissue is not necessarily an
intrinsic negative prognostic factor and its presence alone is not carcinogenic. In
particular, we have consistently found that effects of HA on growth and motility are
dependent on cells synthesizing the HA, and cannot be recapitulated with exogenous
addition of HA to cultures or assays. Rather, the subsequent or concurrent infusion of
hyaluronidase, regardless of cellular origin, leads to accelerated tumor growth and
metastatic spread that is potentiated in the presence of excess HA production. We
propose that more rapid cell cycling and proliferation underlie Hyal1-mediated
metastasis, while Hyal1/HAS cotransfectants are metastatic due to enhanced motility,
independently of any potential effects on tumor angiogenesis. Motility is not increased as
a result of altered extracellular matrix adhesion, but may result from differential use of
adhesion receptors. Since exogenous, extracellular hyaluronidase in vitro and in
subcutaneous tumors also acts on tumor-borne HA, the results collectively imply that
prostate tumor epithelial and stromal cells must both be targeted in therapeutic strategies
involving inhibition of HA production or turnover.

144
3.6

LITERATURE CITED

1.

Pienta KJ, Smith DC: Advances in prostate cancer chemotherapy: a new era
begins, CA Cancer J Clin 2005, 55:300-318; quiz 323-305

2.

Fraser JR, Laurent TC, Laurent UB: Hyaluronan: its nature, distribution, functions
and turnover, J Intern Med 1997, 242:27-33

3.

Stern R: Hyaluronan metabolism: a major paradox in cancer biology, Pathol Biol
(Paris) 2005, 53:372-382

4.

Toole BP: Hyaluronan promotes the malignant phenotype, Glycobiology 2002,
12:37R-42R

5.

Toole BP: Hyaluronan: from extracellular glue to pericellular cue, Nat Rev
Cancer 2004, 4:528-539

6.

Rooney P, Kumar S: Inverse relationship between hyaluronan and collagens in
development and angiogenesis, Differentiation 1993, 54:1-9

7.

Aaltomaa S, Lipponen P, Tammi R, Tammi M, Viitanen J, Kankkunen JP, Kosma
VM: Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence
in Local Prostate Cancer, Urol Int 2002, 69:266-272

8.

Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski
P, Eskelinen M, Kosma VM: Hyaluronan in peritumoral stroma and malignant
cells associates with breast cancer spreading and predicts survival, Am J Pathol
2000, 156:529-536

9.

Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS,
Lokeshwar VB: Comparison of the prognostic potential of hyaluronic acid,

145
hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer,
Int J Cancer 2004, 112:121-129
10.

Lokeshwar VB, Obek C, Soloway MS, Block NL: Tumor-associated hyaluronic
acid: a new sensitive and specific urine marker for bladder cancer [published
erratum appears in Cancer Res 1998 Jul 15;58(14):3191], Cancer Res 1997,
57:773-777

11.

Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar
VB: Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase
(HYAL1) for prostate cancer, Cancer Res 2003, 63:2638-2644

12.

Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR,
Horsfall DJ: Elevated levels of versican but not decorin predict disease
progression in early-stage prostate cancer, Clin Cancer Res 1998, 4:963-971

13.

Noordzij MA, van Steenbrugge GJ, Verkaik NS, Schroder FH, van der Kwast TH:
The prognostic value of CD44 isoforms in prostate cancer patients treated by
radical prostatectomy, Clin Cancer Res 1997, 3:805-815

14.

Bharadwaj AG, Rector K, Simpson MA: Inducible hyaluronan production reveals
differential effects on prostate tumor cell growth and tumor angiogenesis, J Biol
Chem 2007, 282:20561-20572

15.

Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA: Hyaluronidase
expression induces prostate tumor metastasis in an orthotopic mouse model, Am J
Pathol 2006, 169:1415-1426

146
16.

Simpson MA: Concurrent expression of hyaluronan biosynthetic and processing
enzymes promotes growth and vascularization of prostate tumors in mice, Am J
Pathol 2006, 169:247-257

17.

Simpson MA, Reiland J, Burger SR, Furcht LT, Spicer AP, Oegema TR, Jr.,
McCarthy JB: Hyaluronan synthase elevation in metastatic prostate carcinoma
cells correlates with hyaluronan surface retention, a prerequisite for rapid
adhesion to bone marrow endothelial cells, J Biol Chem 2001, 276:17949-17957

18.

Simpson MA, Wilson CM, Furcht LT, Spicer AP, Oegema TR, Jr., McCarthy JB:
Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells
alters pericellular matrix retention and adhesion to bone marrow endothelial cells,
J Biol Chem 2002, 277:10050-10057

19.

Simpson MA, Wilson CM, McCarthy JB: Inhibition of prostate tumor cell
hyaluronan synthesis impairs subcutaneous growth and vascularization in
immunocompromised mice, Am J Pathol 2002, 161:849-857

20.

McCarthy JB, Turley EA, Wilson CM, Price M, Bullard KM, Beck M, Simpson
MA: Hyaluronan biosynthesis in prostate carcinoma growth and metastasis., In
Hyaluronan:

Structure,

Metabolism,

Biological

activities,

Therapeutic

Applications; Chapter 4, Hyaluronan and Tumors. 2005, Editors E.A. Balasz and
V.C. Hascall:
21.

Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW: Quantitative assessment of
angiogenesis and tumor vessel architecture by computer-assisted digital image
analysis: effects of VEGF-toxin conjugate on tumor microvessel density,
Microvasc Res 2000, 59:368-376

147
22.

Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL,
Nadji M, Lokeshwar BL: Stromal and epithelial expression of tumor markers
hyaluronic acid and HYAL1 hyaluronidase in prostate cancer, J Biol Chem 2001,
276:11922-11932.

23.

West DC, Hampson IN, Arnold F, Kumar S: Angiogenesis induced by
degradation products of hyaluronic acid, Science 1985, 228:1324-1326

24.

Kosaki R, Watanabe K, Yamaguchi Y: Overproduction of hyaluronan by
expression of the hyaluronan synthase Has2 enhances anchorage-independent
growth and tumorigenicity, Cancer Res 1999, 59:1141-1145

25.

Liu N, Gao F, Han Z, Xu X, Underhill CB, Zhang L: Hyaluronan synthase 3
overexpression promotes the growth of TSU prostate cancer cells, Cancer Res
2001, 61:5207-5214.

26.

Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL: HYAL1
hyaluronidase in prostate cancer: a tumor promoter and suppressor, Cancer Res
2005, 65:7782-7789

27.

Bullard KM, Kim HR, Wheeler MA, Wilson CM, Neudauer CL, Simpson MA,
McCarthy JB: Hyaluronan synthase-3 is upregulated in metastatic colon
carcinoma cells and manipulation of expression alters matrix retention and
cellular growth, Int J Cancer 2003, 107:739-746

28.

Itano N, Sawai T, Miyaishi O, Kimata K: Relationship between hyaluronan
production and metastatic potential of mouse mammary carcinoma cells, Cancer
Res 1999, 59:2499-2504

148
29.

Delpech B, Laquerriere A, Maingonnat C, Bertrand P, Freger P: Hyaluronidase is
more elevated in human brain metastases than in primary brain tumours,
Anticancer Res 2002, 22:2423-2427.

30.

Rooney P, Kumar S, Ponting J, Wang M: The role of hyaluronan in tumour
neovascularization (review), Int J Cancer 1995, 60:632-636

31.

West DC, Kumar S: The effect of hyaluronate and its oligosaccharides on
endothelial cell proliferation and monolayer integrity, Exp Cell Res 1989,
183:179-196

32.

Enegd B, King JA, Stylli S, Paradiso L, Kaye AH, Novak U: Overexpression of
hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking
hyaluronidase activity, Neurosurgery 2002, 50:1311-1318.

33.

Itano N, Sawai T, Atsumi F, Miyaishi O, Taniguchi S, Kannagi R, Hamaguchi M,
Kimata K: Selective expression and functional characteristics of three mammalian
hyaluronan synthases in oncogenic malignant transformation, J Biol Chem 2004,
279:18679-18687

34.

Udabage L, Brownlee GR, Nilsson SK, Brown TJ: The over-expression of HAS2,
Hyal-2 and CD44 is implicated in the invasiveness of breast cancer, Exp Cell Res
2005, 310:205-217

35.

Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL,
Nadji M, Lokeshwar BL: Stromal and epithelial expression of tumor markers
hyaluronic acid and HYAL1 hyaluronidase in prostate cancer, J Biol Chem 2001,
276:11922-11932

149
36.

Harada H, Takahashi M: CD44-dependent intracellular and extracellular
catabolism of hyaluronic acid by hyaluronidase-1 and -2, J Biol Chem 2007,
282:5597-5607

37.

Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML,
Calabro A, Jr., Kubalak S, Klewer SE, McDonald JA: Disruption of hyaluronan
synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated
transformation of epithelium to mesenchyme [see comments], J Clin Invest 2000,
106:349-360

38.

Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of
multiple receptor tyrosine kinases in epithelial and carcinoma cells, J Biol Chem
2006, 281:34936-34941

39.

Toole BP, Zoltan-Jones A, Misra S, Ghatak S: Hyaluronan: a critical component
of epithelial-mesenchymal and epithelial-carcinoma transitions, Cells Tissues
Organs 2005, 179:66-72

40.

Ghatak S, Misra S, Toole BP: Hyaluronan constitutively regulates ErbB2
phosphorylation and signaling complex formation in carcinoma cells, J Biol
Chem 2005, 280:8875-8883

41.

Ghatak S, Misra S, Toole BP: Hyaluronan oligosaccharides inhibit anchorageindependent growth of tumor cells by suppressing the phosphoinositide 3kinase/Akt cell survival pathway, J Biol Chem 2002, 277:38013-38020

42.

Zhu D, Bourguignon LY: The ankyrin-binding domain of CD44s is involved in
regulating hyaluronic acid-mediated functions and prostate tumor cell
transformation, Cell Motil Cytoskeleton 1998, 39:209-222

150
43.

Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I: Inhibition of tumor
growth in vivo by hyaluronan oligomers, Int J Cancer 1998, 77:396-401

44.

Evanko SP, Wight TN: Intracellular localization of hyaluronan in proliferating
cells, J Histochem Cytochem 1999, 47:1331-1342

45.

Koike C, McKee TD, Pluen A, Ramanujan S, Burton K, Munn LL, Boucher Y,
Jain RK: Solid stress facilitates spheroid formation: potential involvement of
hyaluronan, Br J Cancer 2002, 86:947-953

46.

Lin G, Stern R: Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling,
Cancer Lett 2001, 163:95-101.

47.

Gakunga P, Frost G, Shuster S, Cunha G, Formby B, Stern R: Hyaluronan is a
prerequisite for ductal branching morphogenesis, Development 1997, 124:39873997

48.

Ito T, Williams JD, Al-Assaf S, Phillips GO, Phillips AO: Hyaluronan and
proximal tubular cell migration, Kidney Int 2004, 65:823-833

49.

Ito T, Williams JD, Fraser D, Phillips AO: Hyaluronan attenuates transforming
growth factor-beta1-mediated signaling in renal proximal tubular epithelial cells,
Am J Pathol 2004, 164:1979-1988

50.

Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall
VR, Tilley WD, Horsfall DJ: Formation of Hyaluronan- and Versican-rich
Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility, J Biol Chem
2007, 282:10814-10825

151
51.

Brinck J, Heldin P: Expression of recombinant hyaluronan synthase (HAS)
isoforms in CHO cells reduces cell migration and cell surface CD44, Exp Cell
Res 1999, 252:342-351

152

CHAPTER 4

DIFFERENTIAL ERK ACTIVATION AND REGULATION OF CELL CYCLE CHECK
POINT PROTEINS BY ALTERED HA METABOLISM
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4.1

ABSTRACT
HA plays a crucial role in prostate tumorigenesis and metastasis. We have shown

previously that maximum tumorigenic and metastatic potential of HA is obtained by
concurrent expression of hyaluronan synthase (HAS) and hyaluronidase (Hyal1). These
effects were chiefly due to enhanced cell proliferation, adhesion and motility in the coexpressing cells. In contrast the cells expressing HAS alone, showed growth suppression
in vitro and in vivo and reduced motility. Detail characterization of cell cycle progression
in these cells revealed that expression of Hyal1 alone caused accelerated entry into cell
cycle, whereas HAS alone caused diminished entry. In the present study we establish that
the altered cell cycle kinetics in these cells is predominantly mediated by the reduced
expression of the cyclin dependent kinase inhibitor (CKIs) p21cip (p21) in Hyal1
expressing cells, whereas the HAS expressing cells showed increased expression of both
CKIs p21cip (p21) and p27kip (p27), in both asynchronous and synchronized cultures. We
also demonstrate that the growth factor induced ERK activation was significantly reduced
in Hyal1 expressing cells compared to HAS3 and control (GFP) transfectants. These
studies institute a mechanistic correlation between the tumorigenesis effects observed
earlier, as a consequence of altered HA metabolism.
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4.2

INTRODUCTION
Hyaluronan (HA) is a high molecular weight glycosaminoglycan polymer of

alternating glucuronic acid and N-acetylglucosamine that functions in normal and
pathological tissue to influence cell motility and proliferation1. In radical prostatectomy
specimens from prostate cancer patients, concurrent positive staining for HA and its
degradative/turnover enzyme, the hyaluronidase Hyal1, predicts poor prognosis and
patient outcome2. In animal models, it has independently been shown that HA
overproduction by HA synthase enzymes3, and elevated hyaluronidase activity conferred
by Hyal1 overexpression4, will each promote tumor growth dose dependently, but will
also suppress tumor growth at levels beyond a threshold value. Thus, it is important to
characterize the respective roles of the HA synthases and hyaluronidases in component
processes of tumor progression such as motility and proliferation.
Previous work in our laboratory has shown that overexpression of HAS2 and
HAS3 in non-metastatic prostate tumor cells accelerates growth and lymph node
metastasis of orthotopic tumors in mice, but only in the presence of Hyal1, which can
also accelerate metastasis independently5. When we characterized these stably transfected
cell lines in vitro, we observed that overexpression of HAS2 or HAS3 reduced growth in
culture, whereas Hyal1 transfectants grew faster than the stable control cells. Addition of
exogenous hyaluronidase to HA over-producing cell lines also relieved growth inhibition
by HA polymer production. Similarly, motility was enhanced by expression of Hyal1,
either alone or in conjunction with HAS. Analysis of cell cycle distribution in
asynchronous cultures showed specifically an increase in number of Hyal1 transfectants
in S-phase with concurrent reduction in G0/G1 phase cells. Using nocodazole
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synchronized transfectants, the increased number of S-phase cells was explained by
accelerated re-entry of Hyal1 transfectants to S-phase upon release from arrest. In
contrast, HAS3 transfectants reached and completed S-phase significantly more slowly
than control cells. These studies have determined that the predominant mechanism of
growth control in the Hyal1 and HAS+Hyal1 transfectants is through alterations in DNA
synthesis and cell cycle progression kinetics, prompting us to investigate the molecular
signals linking Hyal1 hyaluronidase and modulation of cell cycle regulatory proteins.
Progression through the cell cycle is dependent on external signals in the
microenvironment until a point in the cell cycle known as the restriction point6, beyond
which the cell is committed to proceed through the cycle irrespective of external cues.
Growth factors or mitogens, integrins and extracellular matrix (ECM) proteins are among
the signals crucial for tight regulation of cell cycle progression through specific
cascades7. The Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein
(MAP) kinase pathway is critical for transmission of extracellular signals to the
nucleus8,9. Nuclear ERK phosphorylates transcription factors that activate an array of
immediate early genes, such as cyclin D1, which are responsible for cell cycle control10.
In response to growth factors or ECM adhesion, passage through the restriction point is
determined by induction of cyclin D1, followed by its binding to the cyclin dependent
kinases CDK4/6, which in turn are activated to phosphorylate the protein Rb.
Hyperphosphorylation of Rb results in the release of E2F transcription factors, inducing
cyclin E and cyclin A during G1/S-phase transition and peak S-phase. To counteract the
effect of the CDK, a group of proteins known as cyclin dependent kinase inhibitors (CKI)
bind to and inactivate the CDKs, thereby stalling progression through the cell cycle. Two
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CKIs, p21Cip and p27Kip bind to CDK4/6 during G1 phase and to CDK2 during S-phase,
inhibiting progression through these phases11-14.
In this study we have investigated the effect of cell cycle arrest and release on
ERK phosphorylation in prostate tumor cells expressing HAS and Hyal1 genes and the
subsequent status of various cell cycle regulatory proteins. We show that there is no
compromised transient or sustained ERK activation in response to growth factors such as
EGF and bFGF in cell expressing HAS enzymes despite the reduced growth and cell
cycle entry in these cells. Interestingly we observed significant downregulation of p21 in
Hyal1 and Hyal1+HAS3 expressing cells, in contrast to the HAS expressing cells, in
which levels of both p21 and p27 were increased. Thus, regulation of CKI is one
potential mechanistic explanation for the differential effects of HA metabolism on cell
cycle progression and tumor growth.

4.3

MATERIALS AND METHODS

4.3.1

Cell Culture, Materials, and Reagents
22Rv1 human prostate adenocarcinoma cells15 were purchased from ATCC and

maintained in RPMI 1640 medium containing 10% fetal bovine serum. Selection,
characterization, and maintenance of 22Rv1 stable transfectants in standard medium
containing 1.5 mg/ml G418 was carried out as described previously15. The pIRES2-EGFP
vector and plasmids pTet-On and pTRE-Tight that comprise the tetracycline-inducible
mammalian expression system were obtained from Clontech (Palo Alto, CA).
Doxycycline and Tet System-approved fetal bovine serum were also from Clontech.
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Antibodies against ERK1/2, phosphorylated ERK1/2, Cyclin A, Cyclin D1, p21 and p27
were from Cell Signaling Technologies (Beverly, MA). The anti-tubulin antibody and
nocodazole were purchased from Sigma. EGF and bFGF were obtained from R&D
Systems (Minneapolis, MN).

4.3.2

Growth Factor Stimulation of Prostate Tumor Cell Lines
For transient activation of ERK1/2, stable transfectants were seeded at 4x105 cells

per well of a 6-well plate in serum containing media. Subconfluent cells were serum
starved for 24 hours, then treated with a cocktail of EGF (20 ng/ml) and bFGF(10 ng/ml).
After

20

mins,

cells

were

washed

twice

in

1x

PBS

and

harvested

in

Radioimmunoprecipitation assay buffer (RIPA: 50mM Tris-HCl, pH 7.5, with 150mM
NaCl, 1% NP-40, and 0.25% sodium deoxycholate) lysis buffer containing 2mM PMSF,
2mM sodium orthovanadate, 2mM sodium fluoride, 1x phosphatase inhibitor cocktail
(Pierce), and protease inhibitor cocktail (Sigma). The harvested cells were quickly
snap/flash frozen under liquid nitrogen and stored at -800C until further use. For long
term evaluation of ERK1/2 activation, 24 hour serum starved cells were treated with
growth factor cocktail (20ng/ml EGF+10ng/ml bFGF) and cell were harvested at 0hrs,
3hrs, 6hrs, 12hrs and 24 hrs using the RIPA lysis buffer described above.
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4.3.3

Cell Synchronization
Cells were synchronized at G2/M phase using the mitotic inhibitor nocodazole 0.2

μM for 24hrs and washed three times with serum free media. The cells were then
released with serum free media containing the growth factor cocktail described above and
harvested by lysis in RIPA buffer at 0 hr, 3hr, 6hr, 12hr and 24 hrs after release.
Asynchronous cells were harvested from 6-well plates which were seeded in serum
containing media.

4.3.4

Kinase Inhibitor Treatment
Subconfluent cultures of stable transfectants were treated with 10µM of U0126

(MEK inhibitor) or 100nM of Wortmannin (PI3K inhibitor) for two hours. The cells were
washed with 1x PBS and harvested in RIPA lysis buffer with protease and phosphatase
inhibitors. Equivalent amounts of protein (10 µg) were separated by SDS-PAGE and
probed using anti-phospho-ERK, total ERK and tubulin antibodies.

4.3.5

Western Analysis
Protein content was adjusted to equivalent levels in all cell lysates following

quantification by Bradford assay. Ten µg of total protein were separated by SDS-PAGE
and transferred to PVDF membrane. Blocked membranes were probed for ERK1/2
(1:1000), phosphorylated ERK (1:1000), cyclin A (1:2000), cyclin D1 (1:2000), p21
(1:2000, or p27 (1:1000), then stripped and reprobed for the tubulin loading control
(1:500,000). The blots were developed using ECL system (Amersham/GE Healthcare,
UK).
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4.3.6 Densitometry Analysis of Western Images
The bands obtained from immunoblots were quantified using the Totallab TL100
V2006b software at the Proteomics Core facility of UNL. Individual protein bands were
normalized to tubulin control. The data are representative of two or three independent
experiments showing similar trends.

4.3.7

Characterization of Tet-inducible 22Rv1 Cells
A 22Rv1 stable line expressing the tetracycline transactivator (as described

previously16) was transfected with pTRE-Tight derived plasmids expressing the GFP
(control), Hyal1, and HAS3 coding sequences under the control of a tetracycline
responsive promoter. The transfectants were induced by applying 2μg/ml of doxycycline
and soluble extracts were prepared for western analysis at 48hrs post induction. The
supernatants were harvested and processed as described15,16 for quantification of HA in
the HAS3 expressing cells.
To determine the proliferation rate of the cells transiently transfected with GFP,
Hyal1 and HAS3, triplicate wells for each cell line were seeded in 24 well culture dishes
24 hours after transfection. The cells were induced with 2μg/ml of doxycycline 24 hours
after plating and the growth was monitored daily for a period of five days by manual
counting. Total number of cells per well were plotted for each day in culture. The plot
shown is representative of four independent experiments.
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4.4

RESULTS

4.4.1 EGF and bFGF Activate ERK Comparably in Prostate Tumor Cell
Transfectants
Our previous studies have demonstrated that HA levels directly correlate with the
suppression of intrinsic growth rate in culture. Expression of Hyal1 enhanced intrinsic
proliferation in culture. To determine the molecular mechanism for these altered growth
kinetics, we decided to evaluate the growth factor signaling pathway in these cells. The
ERK pathway regulates cellular proliferation, differentiation, migration and invasion in
tumor cells. The ERK cascade is a central element in the transmission of signals from the
cell surface to the nucleus. With the idea that ERK is a common downstream effector and
that multiple pathways converge on ERK, we evaluated the effect of growth factors on
ERK activation in cells overexpressing Hyal1 and HAS3. These cell lines were chosen
initially since we saw significant difference in cell cycle progression kinetics between
Hyal1 and HAS3 stable transfectants. GFP control, Hyal1 and HAS3 transfectants were
serum starved for 24 hours, then treated with EGF and bFGF for 20 mins and analyzed by
western blot for levels of transiently activated phospho-ERK relative to total ERK. As
shown in Fig 4.1, the phospho-ERK level was negligible in untreated cells, but increased
dramatically in all three lines upon growth factor addition. The level of phospho-ERK
was consistent among the three transfectants.
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Figure 4.1 EGF and bFGF activate ERK comparably in prostate tumor cell
transfectants. Transient activation of ERK in stable cell lines expressing GFP (control),
Hyal1(Hy1) and Has3(H3) in response to growth factors. We treated 24 hours serum
starved cells with growth factor cocktail (GF) composed of 20ng/ml of EGF and 10ng/ml
of bFGF for 20 mins. Untreated cells (-) and treated cells (+) in each case were harvested
and lysed in RIPA buffer with protease and phosphatase inhibitors. The cell lysates were
collected and ERK1/2 phosphorylation was assessed by western blot analysis. The blot is
representative of three independent experiments.
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4.4.2

Hyal1 Overexpression Reduces Sustained ERK Activation without Altering

Cyclin D1
The MAPK-ERK pathway is known to elicit different biological outcomes
depending on the duration, magnitude and temporal activation of ERK9,10. Sustained
ERK activation is critical for inducing immediate early genes during the G1 phase. One
of these, cyclin D1, is needed for cell cycle re-entry and progression into S-phase, and is
not induced by transient activation of ERK17-20. We evaluated the effect of growth factors
on sustained ERK activation and cyclin D1 expression in the Hyal1 and HAS
transfectants (Fig 4.2). Serum starved cells were treated with EGF and bFGF for 3h and
12h, which correspond to mid G1 and late G1, respectively. Serum starvation (SSM) did
not decrease phospho-ERK levels relative to cells in serum containing media (AS).
Growth factor treatment of serum starved cells resulted in significant increase in
phospho-ERK levels, in all three cell lines at 3h after stimulation (GF+3h). Total ERK
levels were uniform in all conditions tested. This increase in phospho-ERK was sustained
up to 12h (GF+12h) in control and HAS3 cells. However, in Hyal1 expressing cells,
phospho-ERK was already significantly reduced at 3h after growth factor stimulation and
remained low at 12h. Levels of cyclin D1 were not altered by serum starvation or growth
factor stimulation in any of the cell lines (Fig 4.2). However, as previously reported by
others21, cyclin D1 levels were reduced in serum starved normal fibroblasts and epithelial
cells and were elevated by growth factor induced ERK activation22,23. This is consistent
with our prior evaluation of these cells, in which we were unable to synchronize cultures
by serum starvation. Cyclin D1 overexpression may account for failure of these cells to
synchronize in G0/G1 phase.
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Figure 4.2 Hyal1 overexpression reduces sustained ERK activation without altering
cyclin D1. Cell populations in serum containing (AS) or serum deficient (SSM) media
were treated with growth factor cocktail (GF) composed of 20ng/ml EGF and 10ng/ml
bFGF for 3h (GF+3h), and 12h (GF+12h). Cells were harvested and lysed in RIPA buffer
with protease and phosphatase inhibitors and analyzed by western blot probed with the
indicated antibodies (left). Densitometric quantification of p-ERK2 to t-ERK2 ratio and
cyclin D1 to tubulin ratio is shown at right. Data are from one blot representative of three
independent experiments.
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4.4.3

Hyal1 Overexpression Reduces Growth Factor Mediated ERK Activation in

Synchronized Cells
We have shown previously that treatment with nocodazole, a microtubule
inhibitor arrested 80-85 % of the 22Rv1 transfectant populations in G2/M phase and on
release with serum, they progressed through the cell cycle. Therefore, we tested whether
there were differences in ERK activation when cells were arrested with nocodazole and
released from arrest by addition of growth factors. Examination of phospho-ERK levels
in arrested cells revealed a significant increase in all three cell lines (Fig 4.3). This is
consistent with findings in several studies that show microtubule destabilizing agents
activate kinases such as p38, ERK and JNK.24-26.
When cells were released from arrest by growth factor addition, ERK activation
was sustained, as observed in response to growth factor treatment of serum starved cells
(Fig 4.2). Hyal1 expressing cells again showed reduced levels of phospho-ERK at 12h
after growth factor stimulation. Thus, although there was no significant difference in
transient activation of ERK in cells expressing Hyal1 and HAS3 sustained ERK
activation by growth factors is significantly diminished in Hyal1 cells.
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Figure 4.3 Hyal1 overexpression reduces growth factor mediated ERK activation in
synchronized cells. GFP (control), Hyal1(Hy1) and Has3(H3) expressing cells were
synchronized with 0.2µM nocodazole in serum free media for 24hours. Cells were
released with GF cocktail as described in the Fig 2 legend, and harvested at 3h and 12h
post release. The total protein was assessed for ERK phosphorylation by western blot
(above) and quantified by densitometry (below). The data shown are representative of
three independent experiments.
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4.4.4

Basal ERK Activation in Prostate Tumor Cells is Inhibited by the MEK

Inhibitor U0126
The 22Rv1 prostate tumor cells showed increased basal phospho-ERK levels
which were not modulated by serum starvation. To investigate the upstream pathway that
is responsible for ERK activation we treated the cells with U0126 a specific inhibitor for
both MEK1 and 2 and Wortmannin, which targets the PI3K pathway (Fig 4.4). We
observed complete depletion of phospho-ERK levels in cell treated with U0126 in control
(GFP), Hyal1, HAS3, and Hyal1+HAS3 transfectants. PI3K inhibitor wortmannin failed
to elicit any inhibition in these cells. This suggests that the constitutive ERK activation in
these prostate tumor cells is due to the activation of the Ras/Raf/MEK pathway and not
due the PI3K pathway. The uniform inhibition of phospho-ERK levels in all the
transfectants suggest that there is no difference in ERK activation pathway due to
constitutive expression of HA metabolic enzymes.
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Figure 4.4 Basal ERK activation in prostate tumor cells is inhibited by the MEK
inhibitor U0126. Subconfluent cultures of 22Rv1 stable transfectants were treated with
vehicle (DMSO), 10µM UO126 (MEK inhibitor) and 100nM Wortmannin (PI3K
inhibitor) for 2 hours. The cells were harvested and equivalent protein was assessed by
western blot for p-ERK, t-ERK and Tubulin.
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4.4.5

Expression of Cyclin Dependent Kinase Inhibitors in Hyal1 and HAS3

Transfectants Inversely Reflects their Growth Kinetics
Since we did not observe regulation of cyclin D1 protein levels by growth factors,
we examined additional cell cycle regulatory components that could underlie the altered
growth of these cells. Cell cycle kinase inhibitors p21cip (p21) and p27kip (p27) also
regulate cell cycle progression. We analyzed p21 and p27 in asynchronous cultures of
transfectants expressing Hyal1, either HAS2 or HAS3, and Hyal1+HAS3 cotransfectants
(Fig 4.5A). p21 protein levels were significantly lower in Hyal1 and Hyal1+HAS3 cells
compared to control GFP. In contrast and consistent with their slower proliferation,
HAS2 and HAS3 transfectants had 2.3 fold higher p21 expression than controls.
Similarly, p27 protein was modestly higher in HAS2 and HAS3 expressing cells (2 fold),
relative to controls. In Hyal1 and Hyal1+HAS3 expressing cells, there was no significant
change in p27.
To determine if p21 and p27 protein levels are modulated during cell cycle
progression, we synchronized cells with nocodazole (Noc Arr) and probed for p21 (Fig
4.5B) or p27 (Fig 4.5C) at 12h after release with growth factor addition (Rel+GF+12h).
Nocodazole arrest reduced p21 and p27 slightly in all three cell lines. However,
expression of both proteins remained lower in Hyal1 transfectants relative to control or
HAS3 cells. The expression of p21 was elevated in both Hyal1 and HAS3 lines at 12h
after release from arrest by mitogen addition, with HAS3 cells exhibiting the greatest
increase.
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Figure 4.5 Expression of cyclin dependent kinase inhibitors in Hyal1 and HAS3
transfectants inversely reflects their growth kinetics. (A) Equal amounts of protein
from serum replete asynchronous cultures of 22Rv1 stable transfectants expressing GFP
(control), Hyal1 (Hy1), HAS2 (H2), HAS3 (H3) and Hy1+HAS3 (Hy1H3) were analyzed
by western blot for p21, p27, and tubulin control. The right panel is a densitometric
representation of the immunoblots. Nocodazole synchronized (Noc Arr) cells were
released with GF cocktail as described above. The cells were harvested at 3h and 12h
post release and assessed for p21 (B) and p27 (C) in comparison to asynchronous (AS)
and synchronized (Noc Arr) cells.
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Overall, the level of both p21 and p27 was decreased in Hyal1 clones and the
level of both p21 and p27 was increased in HAS3 clones. Expression of p21 in control
cells did not change in response to mitogen, whereas both Hyal1 and HAS3 showed an
increase. This result suggests that the predominant effect on cell proliferation and cell
cycle progression in cells expressing Hyal1 and HAS is through altered protein levels of
the CKIs.

4.4.6

Inducible Expression of Hyal does not Enhance Cell Proliferation and

Downregulate p21
To supplement the results obtained for p21 expression with constitutive
expression of Hyal1 and HAS, we evaluated expression of p21 in Tet-22Rv1 cells
transiently induced for expression of Hyal1 and HAS3. Tet-22Rv1 cells were transfected
with GFP (control), Hyal1 and HAS3 plasmids with the tet-responsive promoter using
equivalent DNA concentration for each plasmid. Cells were analyzed 48 hrs post
induction with doxycycline (Dox) (Fig 4.6A). The p21 protein levels increased upon
induction with doxycycline for all three transfectants. The level of p21 was lowest for the
control GFP in the absence of Dox, and highest in Hyal1 and HAS3 induced cells. This
observation was in contrast to our previous observation with the constitutive clones,
where Hyal1 overexpression showed reduced p21 protein levels in both asynchronous
and synchronized cultures.
To investigate underlying causes of this difference, we tested the growth kinetics
of cells induced for Hyal1 and HAS3 expression (Fig 4.6B). The Tet-22Rv1 cells were
transfected and grown in the absence (-D) or presence (+D) of doxycycline for five days.
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Reduction of growth upon induction of GFP became significant, but not until day five
(p<0.05). Surprisingly, induction of Hyal1 also showed significant impact on growth at
days four and five, which was markedly reduced relative to both induced and uninduced
GFP controls. In the case of HAS3 transfectants, induction significantly reduced growth
at day one, which remained depressed on subsequent days. Activity of the induced
transgenes in each of the above lines was confirmed by western blot for expression of
Hyal1, and by HA content of the conditioned media for HAS3 (Fig 4.6C). Like GFP
controls, Hyal1 transfectants lacked Flag epitope signal in the absence of Dox (-), but
upon induction (+) showed robust expression. Similarly, we observed negligible HA
production in GFP control cells, with a moderate elevation in uninduced HAS3
transfectants that increased ≈30-fold with induction.
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Figure 4.6 Inducible expression of Hyal does not enhance cell proliferation and
downregulate p21. 22Rv1 Tet-ON cells were transiently transfected with constructs
encoding GFP, Hyal1 or HAS3 under the control of a Tet sensitive promoter. (A)
Expression of p21 was determined in cells uninduced (-) and induced (+) with 1µg/ml of
doxycyline (Dox). (B) Growth of inducible transfectants was assayed by plating equal
numbers of 22Rv1 Tet-ON 22Rv1 cells transiently transfected with inducible GFP (G),
Hyal1 (Hy1) or HAS3 (H3) constructs in the absence (G-D, Hy1-D, H3-D) or presence
(G+D, Hy1+D, H3+D) of 1 µg/ml doxycycline. (C) Expression of Hyal1 protein in
transiently induced cultures was verified along with constitutive Hyal1 stable clone using
anti-flag antibodies.
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4.5

DISCUSSION
The goal of the present study was to elucidate the mechanisms of altered cell

cycle progression in Hyal1 and HAS3 overexpressing cells that differ in their tumorigenic
and metastatic potential. Our studies have identified a potential mechanism for the effects
of Hyal1 and HAS3 overexpression on prostate tumor cell proliferation, cell cycle
progression kinetics and tumorigenesis. The S-phase entry is principally regulated via
CKIs and not via cyclin D1 in these prostate tumor cells.
Sustained ERK activation mediates direct phosphorylation and stabilization of
transcription factors, thereby prolonging their expression and activity as opposed to
transient activation, in which case transcription factors are unstable and degraded10.
Although there was no difference in transient ERK activation among Hyal1 and HAS3
expressing cells, we did observe reduction in sustained ERK activation in Hyal1
expressing cells. This is consistent with studies in which exogenous high molecular
weight HA did not compromise mitogen induced ERK activation27. Increased HA
production by HAS2 overexpression in cancer cell lines has been found to constitutively
activate multiple cell surface growth factor receptors, including EGFR and ERBB2, in a
CD44 dependent manner28. Growth factor mediated sustained ERK activation usually
upregulates cyclin D1. However, we did not observe any significant differences in cyclin
D1 protein among Hyal1 and HAS3 tumor cell transfectants in any conditions tested,
despite an increase in sustained ERK activation. The most obvious explanation is that
tumor cells already overexpress cyclin D1 and are insensitive to further stimulation29.
Although androgen has been shown to modulate cell cycle progression via cyclin D1 in
the parent CWR22 cell line30, 22Rv1 cells have largely lost androgen dependence and
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may be unresponsive to this alternative mode of cyclin D1 regulation. Similarly,
exogenous HA polymer has been shown to reduce S-Phase entry in quiescent vascular
smooth muscle cells and fibroblasts primarily by decreasing cyclin D1 protein levels31. In
our HAS3 overexpressing cells, cyclin D1 is unaffected by mitogen, suggesting
exogenous and endogenous HA acts by different mechanisms.
We observed that intrinsic phospho-ERK levels are elevated in 22Rv1 prostate
tumor cells. ERK is activated primarily by the Ras/Raf/MEK pathway by growth factors
and integrins, but can also be phosphorylated downstream of PI3-kinase via PKC
indirectly and via Centaurin-α1 directly32,33. Inhibition of MEK eliminated ERK
phosphorylation while a PI3-kinase inhibitor had no effect, indicating that the
predominant pathway for ERK activation in our system was via Ras/Raf/MEK. The
22Rv1 prostate tumor cells overexpress ERBB2 (HER2) and EGFR receptors34, which
would be expected to promote hyperactivation of Raf/Ras/MEK. This is a possible
explanation for the elevated basal level of ERK in 22Rv1 parental and transfected cells.
Assessment of the two CKIs p21 and p27 in asynchronous and nocodazole
synchronized cell populations revealed that p21 and p27 protein levels were reduced in
rapidly proliferating Hyal1 transfectants, while these levels were increased in the slower
growing HAS3 cells. This finding is consistent with the well established role of p21 and
p27 as negative regulators of the cell cycle35,36, and stands in contrast to increasing
evidence suggesting p21 can also act as a positive modulator of cell proliferation and
tumorigenesis37-41. It is worth bearing in mind that the inhibitory potential of p21 is
dependent on cellular context, phosphorylation state and protein-protein interaction35.
The upregulation of p21 protein levels in Hyal1 expressing cells 12h after growth factor
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stimulation suggests it is involved in promoting G1/S transition in these cells. Small
amounts of p21 bound to the cyclin/CDK complexes activate the complex for cell cycle
progression, whereas higher amounts inhibit the complex13. Therefore, the opposite result
occurs upon induction of p21 in HAS3 transfectants, which already have high levels: that
is, the increased p21 level inhibits growth. A further explanation for the opposing effects
of p21 and p27 upregulation on Hyal1 versus HAS3 transfectants is that these proteins
also bind to proliferating cell nuclear antigen (PCNA), a DNA polymerase δ processivity
factor, thereby blocking DNA synthesis42. The reduced protein level of p21 in Hyal1
expressing cells is a plausible mechanism for enhanced DNA synthesis and S-phase
entry, while the increased p21 observed in HAS3 cells would conversely reduce DNA
synthesis. Finally, it has also been previously reported that binding of HA polymers to
CD44 antagonized S-phase entry in smooth muscle cells, and that this occurred through
stabilization of p27 via inhibition of Skp2, a component of the p27 degradation
machinery31,43. Our data showing p27 remained elevated in HAS3 up to 12h after
mitogen stimulation are consistent with this regulatory scheme.
One of the possible implications of downregulated p21 in asynchronous and
synchronized Hyal1 transfectants could be reduced DNA damage response. In this study,
we have shown that the shorter residence time in G2 and G1 phase after nocodazole
arrest that we observed in Hyal1 transfectants5 is due to decreased p21 levels. Since p21
is required in DNA damage induced cell-cycle arrest, Hyal1 expressing cells may
continue to synthesize DNA in the absence of proofreading, thus propagating genomic
instability. In contrast, the HAS3 expressing cells may evade such damage by slower
entry into the cell cycle, and are therefore less tumorigenic. We are currently testing the
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effects of DNA damage agents and pathways therein to test this possibility.
The magnitude of ERK activation is important not only in cell cycle progression
but also in cell cycle arrest. The ERK pathway was shown to cause cell cycle arrest in
primary hepatocytes by increased expression of p2144-48. Consistent with this, our study
showed increased ERK activation in HAS3 transfectants at 12h after growth factor
stimulation, a time at which we also observed increases in p21. Moreover, Hyal1 showed
only moderately increased ERK activation at 12h, and also had only a slight increase in
p21 levels, probably not sufficient to cause cell cycle arrest. Further studies using specific
inhibitors that block ERK activation in response to growth factors are warranted to
determine if it has a direct bearing on the induction of p21 in HAS3 expressing cells. Our
studies also have not addressed the reason for differences in magnitude of ERK activation
among the cells expressing Hyal1 and HAS3. The amplitude, duration, and quality of
signals generated by a given ligand such as growth factors are functions of receptor
activation states, quantities, and locations that are determined by regulated intracellular
trafficking10,49. It would be interesting to determine if there are differences in endosomal
trafficking and growth factor receptor internalization in cells overexpressing Hyal1 or
HAS3. It may be informative to perform a gene expression profile of cells treated with
growth factors at the time points where we observe differences in ERK activation, thus
directly correlating genes upregulated and/or downregulated due to the magnitude of
ERK activation.
To support our observations for the effect of Hyal1 and HAS3 constitutive
overexpression on CKIs p21 and p27, we used our inductible expression system. In these
experiments, p21 expression was not downregulated by induction of Hyal1 as we
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observed with the constitutive clones. On the contrary, we observed increased p21 levels
compared to the GFP controls. However, we also observed an increase in p21 protein
level on induction of HAS3, which is consistent with results of constitutive HAS3
expression. Although constitutive expression of Hyal1 significantly increased intrinsic
growth rate of cells5,15,16 compared to control and HAS3 transfectants, transient induction
of Hyal1 had the opposite effect. One probably explanation for this effect is that the
Hyal1 protein level is considerably higher in the induced versus constitutive cell lines.
Hyal1 expression has previously been shown to have a concentration dependent effect on
cell proliferation: that is, low Hyal1 promoted growth while high Hyal1 induced
apoptosis of tumor cells4. Evaluation of apoptosis in our induced cells is underway to
confirm whether this is occurring. Another complicating factor is that we also observed
decreased growth of cells induced for GFP expression. This suggests increased
doxycycline, and/or sudden induction of large-scale protein production, might generally
reduce growth, partly contributing to the Hyal1 induced decrease in growth we observed.
Nonetheless, both induced and constitutive HAS3 expression reduced intrinsic cell
growth16. Here we correlated growth reduction with p21 levels, which are modestly
elevated by HAS3 expression. We propose the differences in growth and other
tumorigenic phenotype between the constitutive and inducible systems may also be
attributable to stable adaptation to long term expression of Hyal1 or HAS3. We are now
doing experiments to systematically assess the effects of concentration dependence of
Hyal1 expression on growth by varying the levels of dox/induction (used for induction).
This will allow us to control the Hyal1 expression and simultaneously monitor its effect
on growth and p21 protein levels.
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In summary, we have discovered a plausible signaling mechanism for the altered
growth and cell cycle kinetics of prostate tumor cells in response to altered HA
metabolism. We propose that modulation p21 and p27 protein expression could be a
potential mode of regulation in these prostate tumor cells.
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CHAPTER 5

SUMMARY AND FUTURE DIRECTIONS
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5.1

SUMMARY
Hyaluronan (HA) has been regarded as an important extracellular matrix (ECM)

involved tumor growth and progression. The studies described in the previous three
chapters of this thesis have contributed to the understanding of the role of HA in tumor
development. We understand that HA does not merely play a mechanical and structural
role facilitating the migration of tumor cells in ECM, but is actively involved in
regulating cellular processes governing tumor progression such as tumor cell proliferation
and motility.
The primary focus of our studies has been to dissect the respective roles of the
HA metabolic enzymes, hyaluronan synthases and hyaluronidases, in prostate tumor
progression. To complement correlative studies between HA/Hyal1 and poor patient
prognosis in prostate cancer, we used gene manipulation techniques to overexpress the
synthases HAS2 and HAS3 and the hyaluronidase Hyal1 in a non-metastatic prostate
tumor cell. Using both in vitro and in vivo characterizations, we established that
concurrent expression of HAS and Hyal1 is necessary for maximum tumorigenesis and
metastasis. Overproduction of large quantities of HA polymer causes suppression of
tumor growth and spontaneous lymph node metastasis. This is correlated with poor
growth of cultured cells in vitro (chapter 2 and 3), and decreased migration in response to
ECM substrates such as collagen (chapter 3). Interestingly, supplementation of
exogenous hyaluronidase or coexpression of Hyal1 restored the growth in vitro and also
enhanced tumor growth and metastasis in vivo. The increase in metastasis correlated well
with increased adhesion and migration to collagen. Decreased integrin mediated adhesion
of HAS expressing cells could not only explain the reduced metastatic potential of these
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cells but could also account for the growth suppressive properties of HA. Adhesion is
critical for tumor cell motility, but also plays a critical role in regulating apoptosis, cell
cycle and proliferation. Most importantly, turnover of excessive HA is critical in
mediating enhanced adhesion and motility. Thus, our studies show that excess HA in
tumors by increased synthesis is not necessarily a negative indicator of tumor progression
and presence of HA alone is not tumorigenic. We now understand exogenous HA does
not promote the same effects on prostate tumor cells as cells actually synthesizing the
HA. In contrast, both exogenous hyaluronidase and Hyal1 synthesized by the tumor cell
itself promote cell growth and metastasis only in the presence of excess HA.
Tumor growth and metastasis were independent of angiogenesis. We believe the
increased proliferation and metastasis of Hyal1 transfectants was largely dependent on
accelerated cell cycling and enhanced cell motility. Metastasis of HAS+Hyal1
transfectants was not correlated with cell cycle or intrinisic proliferation in culture, but
was commensurate with increased motility, and probably due to altered integrin receptor
engagement. Consistent with another report, we showed that Hyal1 expression promoted
cell cycling with higher rate of entry to S-phase and shorter residence in G0/G1 phase,
while HAS expressing cells resided longer in G0/G1 and consequently were slower to
enter S-phase. Intracellular and extracellular HA has been reported to play a role in
mitosis by supporting de-adhesion of cells during mitotic cell rounding. Intracellular HA
can also impose steric hindrance by inhibiting DNA synthesis unless balanced by
concurrent Hyal1 expression to promote cell cycling. In chapter 4, our goal was to
determine the signaling mechanisms underlying altered cell cycle kinetics. Accelerated
entry and increased fraction of cells in S-phase, in both Hyal1 expressing and
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Hyal1+HAS3 coexpressing lines, were accompanied by reduced levels of p21. Moreover,
both p21 and p27 were increased in HAS expressing cells, which could explain their
reduced DNA synthesis (chapter 4). Further validation of this involvement is required.
Experiments evaluating the activation of cyclin dependent kinases such as CDK4/6 and
phosphorylation of Rb during cell cycle progression will throw further light on the effect
of the CKIs in these cells.

5.2

SIGNIFICANCE
HA has been suggested to participate in tumor growth and CaP progression1-3,

consistent with the elevated HA levels around both tumor cell and tumor stroma in tumor
samples. Overexpression of the HA synthases has shown to promote tumorigenesis in
many cancer models4-7. None of these studies addressed the involvement of Hyal in such
processes. The studies described in this report on the contrary suggest that overexpression
of HA synthases alone is tumor suppressive. We observed maximum tumor growth in
prostate only by concurrent expression of HAS and Hyal1 (Chapter 2 and 3). This is a
significant finding, indicating dual requirement of both metabolic enzymes for maximum
tumorigenesis. We also observed requirement of both HAS and Hyal1 for promoting
enhanced metastases to lymph nodes, which is a novel finding (Chapter 2 and 3). Our
studies have also attributed that the enhanced tumor growth, metastatic potential is
primarily due to effects on cell proliferation, cell cycle, adhesion and motility and not due
to angiogenesis. This is again intriguing, since overexpression of Hyal1 has previously
shown to promote angiogenesis. In contrast to our expectation we did not see significant
correlation between intratumoral vascularity and tumor size and metastatic potential.
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Since HA influences angiogenesis in a size dependent manner, we need to further
investigate the size of oligomers generated as a result of co-expression of HAS and
Hyal1.
Another significant highlight of our study is the differential effect of exogenous
HA versus that produced endogenously by synthases. A vast array of study in the
literature observed effects of exogenous HA on cell proliferation, motility and
intracellular signaling pathway, whereas our studies failed to identify such a relationship.
In our system exogenous high molecular weight HA did not elicit growth suppression as
we observed with endogenous expression of HAS. We also did not see any remarkable
changes in ERK phosphorylation in presence of exogenous HA (data not shown). This
discrepancy in findings might be due to variations in cell type specificity, but highlights
the important role of HAS and endogenous production of HA in tumorigenesis.
Meanwhile we also observed that exogenous addition hyaluronidase mediated similar
effects as the co-expression of Hyal1 and HAS, suggesting the source of the
hyaluronidase could be from stromal compartment.
From these studies it is enticing to speculate that HAS and Hyal1 might function
in a chronological order in CaP progression, where initial overexpression of HAS and HA
production alone can be tumor suppressive either by suppressing tumor cell proliferation,
but also by suppressing immune response. But subsequently tumor cells might induce
expression of Hyal to ameliorate the growth suppressive effects and promote aggressive
disease progression.
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5.3

FUTURE DIRECTIONS
The current research has led to several interesting questions, prompting future

work in the relevant areas. Some of the possible avenues have been outlined below.

5.3.1 Does HA Metabolic Enzymes have a Role in DNA Damage Response?
The cell cycle progression studies have shown that Hyal1 expressing cells have
reduced residence time in G0/G1. We also know this can be attributed to reduced levels
of p21, an important cyclin dependent kinase inhibitor (CKI) that regulates cell cycle
progression. p21 plays a protective role during DNA damage in normal cells8. The
expression of p21 is directly induced by the DNA damage sensor p53 in response to
DNA damaging agents. p21 then causes cell cycle arrest and allows the cell to repair the
damaged DNA. Cells lacking p21 appear to arrest, but they continue to synthesize their
DNA. This probably results in abnormal DNA content and genomic instability,
sometimes but not always leading to cell death by apoptosis9-11. However, p21 also plays
a role in inhibiting apoptosis, where p21 becomes cytoplasmic during monocytic or
neuronal differentiation and interacts with pro-apoptotic proteins SAP and ASK1 kinases
and also prevents procaspase-3 activation, preventing their catalytic activity and
apoptotic function12-15. The decreased expression of p21 in Hyal1 expressing cells and
Hyal1+HAS3 co-expressing cells correlates with the increased rate of S-phase entry in
these cells and also with the enhanced fraction of cells in the S-phase compared to the
control. Does this mean that these cells are compromised in their DNA damage
mechanisms and continue to synthesize new DNA, with a higher probability for
incorporated mutations? Such mutations could then accumulate and result in genomic
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instability, one of the hallmarks of tumorigenesis and a key underlying factor in tumor
progression. We are collaborating to explore this aspect by examining DNA damage
response pathways activated (or not activated) in our prostate tumor cell transfectants,
and the DNA damage check point proteins in these cells.

5.3.2 Mechanism of p21 Downregulation in Hyal1 Expressing Cells and p27
Upregulation in HAS Expressing Cells
The results described in chapter 4 suggest that CKIs p21 and p27 are potential
candidates for regulation of cell cycling in the prostate tumor cells overexpressing Hyal1,
HAS3 and Hyal1+HAS3. Out data show p21 protein is downregulated in Hyal1 and
Hyal1+HAS3 expressing cells, whereas it appears to be modestly elevated in HAS3
expressing cells along with p27. These preliminary observations raise a number of
important of questions. First, are the changes in protein levels of p21 and p27 due to
transcriptional

regulation

or

due

to

post-translational

modification?

Protein

phosphorylation is a key regulatory mechanism employed by cells to regulate function,
localization and stability of p21 and p2716. Phosphorylation of critical serine (S146) and
threonine (T145) residues in p21 by kinases such as PKCς (protein kinase C ς) and Akt,
respectively, affect p21 stability. Furthermore, p21 interacts directly with the proteosome,
which probably accounts for its ubiquitin-independent degradation, and this may be
dependent on protein modification16. An interesting aspect of the p21 and p27 group of
proteins is that they are both unstructured proteins that adopt an ordered structure only
upon binding to a protein partner17. Thus, another research question is whether Hyal1
overexpression affects, either directly or indirectly, p21 expression and/or stability.
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Direct interaction of p21 and Hyal1 leading to decreased p21 stability seems highly
unlikely, but an indirect mechanism could be mediated through Akt (phosphorylation and
stabilization) or through p53 (transcriptional regulation). Studies by other groups have
shown that exogenous HA polymer increases p27 protein level by stabilizing the protein
in mitogen stimulated vascular smooth muscle cells18. HA polymer mediates this effect in
these cells by inhibiting mitogen-induced cyclin D1 and reducing the expression of Skp2,
a protein involved in the degradation of p27. In our experiments, though we observe an
increase in p27 protein in cells expressing HAS, downregulation of cyclin D1 does not
occur with HA overproduction. This probably implies two scenarios: there are cell type
specific differences in cyclin D1 regulation; or the effect of exogenous HA and HA
synthesized by cells might be quite different, as we and other labs have reported in cell
proliferation studies. Nevertheless, we see increases in p27 levels in HAS expressing
cells, implying that other mechanisms may be relevant in our system.
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